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The accumulation of senescent cells induced by intracellular and extracellular stress contributes 
to multi-organ dysfunction and aging. Persistent DNA damage chronically accumulates with 
aging initiating a cellular stress response termed DNA damage response (DDR). Ataxia-
telangiectasia mutated (ATM) kinase, a core component of DDR signaling, is involved in p53-
p21 and p16-Rb senescent effector pathways, and is essential for senescence-associated secretory 
phenotype (SASP). In addition, ATM activates NEMO-dependent NF-κB pathway in response to 
genotoxic stress. However, the underlying molecular mechanisms through which DNA damage 
drives senescence and aging remain poorly characterized. Here we used the Ercc1-/Δ mouse 
model of a human progeria that spontaneously develops osteoporosis, disc degeneration, 
glomerulonephropathy and neurodegeneration, to address the causal link between DDR-
dependent NF-κB activation, cellular senescence and aging. In the first part, we demonstrated 
that DDR signaling, concomitant with NF-κB, was highly activated in Ercc1-/Δ mice. A causal 
role of ATM in DNA damage-induced aging was demonstrated by genetic depletion of ATM in 
Ercc1-/Δ mice, which extended health span as well as alleviated aging-related pathology. 
Moreover, ATM haploinsufficiency showed significantly reduced NF-κB activation and SASP. 
In vitro assays support an activation of ATM- and NEMO-dependent canonical NF-κB activation 
in response to oxidative stress. In the second part, we developed novel small molecule inhibitors 
to disrupt the interaction between IKKβ and NEMO/IKKγ. We demonstrated that novel NBD 
mimetics, in particular SR12343 and SR12460, efficiently inhibited both TNF-α and LPS-
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induced NF-κB activation in vitro. Additionally, the chronic treatment with SR12343 and 
SR12460 reduced LPS-induced acute inflammation in lung and liver, and improved muscle 
pathology in mdx mice, a murine model of Duchenne muscular dystrophy. In the third part, we 
demonstrated that chronic treatment of Ercc1-/Δ mice with SR12343 significantly improved aging 
symptoms and prolonged healthspan, as well as reduced the level of cellular senescence. 
Furthermore, suppression of IKK/NF-κB attenuated lipodystrophy and associated impaired 
glucose tolerance by reducing cellular senescence in fat. Taken together, these results suggest 
that NF-κB activation promotes cellular senescence and aging through an ATM-dependent 
pathway in Ercc1-/Δ mice and the ATM-IKK-NF-κB pathway represents a key target for the 
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1.0  INTRODUCTION 
1.1 NF-κB SIGNALING PATHWAY 
1.1.1 Introduction to NF-κB 
Nuclear factor-kappa B (NF-κB), a family of transcription factors, was first discovered in B 
lymphocytes by David Baltimore’s lab in 1986 (1). Since then, extensive studies were performed 
revealing NF-κB as pleiotropic transcription factors. Our knowledge of stimuli that activate this 
pathway has expanded from lipopolysaccharide (LPS) and phorbol ester (e.g. PMA), to vast 
numbers of pro-inflammatory factors, oxidative stress and genotoxic stress (2-4). NF-κB was 
also unveiled to be not limited to B cells, but expressed in almost all cell types, regulating 
various essential biological events (5). To date, five NF-κB family members, three IKK complex 
subunits and nine IκB proteins were identified, along with their protein domains, crystal 
structures and biological function utilizing various techniques.  
1.1.2 NF-κB family 
In mammalian cells, the NF-κB family contains five members including RelA/p65, RelB, C-Rel, 
p50 (p105/NF-κB1) and p52 (p100/NF-κB2), all of which share a Rel homology domain (RHD) 
required for DNA binding and homo- or hetero-dimerization (6). RelA, RelB and C-Rel also 
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contain a transactivation domain (TAD) essential for transcriptional activity. The precursors of 
p50 and p52, p105 and p100 respectively, contain an ankyrin repeat-containing domain (ARD), 
which functions to sequester their NF-κB partners in the cytoplasm and prevent activation (3). 
To promote transcriptional activity, cleavage of precursors, p105 and p100, is required, mainly 
through co-translational processing and SCF-βTrCP-dependent or -independent degradation (7-
9). RelA/p65:p50 is the most common heterodimeric combination involved in the canonical 
pathway, while RelB:p52 heterodimers predominate in non-canonical activation (Fig.1). 
 
 
Figure 1: Members of NF-κB family.  Structural motifs of NF-κB subunits are shown. RHD, 
Rel-homology domain; TAD, transactivation domain; LZ, leucine zipper; GRR, glycine-rich 
region; ANK, ankyrin-repeat motifs; DD, death domain. (Figure adapted from Perkins N.D. 2007 
(3) ) 
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1.1.3 IκB kinase (IKK) complex  
NF-κB is mainly activated by IκB kinase (IKK complex), which is the upstream of NF-κB. The 
IKK complex consists of three subunits, including two catalytic subunits, IKKα/IKK1 and 
IKKβ/IKK2, and one regulatory subunit IKKγ/NEMO. IKKα and IKKβ both contain a kinase 
domain, a leucine-zipper-like motif, a helix-loop-helix and a NEMO-binding domain (NBD), and 
are 52% identical to each other, with the kinase domain sharing 65% identity (10). NEMO 
contains two coiled-coil domains, one leucine-zipper domain and a zinc-finger (ZF) region (3). 
May et al. demonstrated that the NBD domain contained within the C-terminus of IKKβ/α is 
indispensible for the assembly and function of the IKK complex (11). In mammalian cells, the 
IKK complex exists as a high-molecular weight multiprotein complex with molecular size 
ranging between 600-900 kDa (10, 12) (Fig. 2).  
            Genetic evidence suggests that subunits of the IKK complexes are distinct, but related in 
function. IKKβ and NEMO knockout mice die on E12-E14 due to massive TNFα-induced 
apoptosis of hepatocytes, similar to RelA/p65 knockout mice (13, 14). This phenotype was later 
shown to be rescued in tumor necrosis factor receptor 1 (TNFR1) deficient mice, suggesting a 
protective role for IKKβ and NEMO in TNF-α-induced apoptosis (13, 15, 16). Of note, NEMO 
deficient cells exhibit a greater loss of NF-κB activity than IKKβ deficient cells (17-19). 
Surprisingly, IKKα knockout mice exhibit a distinct phenotype, including skeletal and epidermal 
abnormalities, rudimentary limbs and craniofacial deformities and die perinatally, suggesting that 
the function of IKKα is different from IKKβ (20-22).  
            In 2000, mutations in NEMO, were linked to two X-linked human genetic disorders, 
incontinential pigmenti (IP) and anhidrotic ectodermal dysplasia associated with 
immunodeficiency (EDA-ID) (23). NEMO is a 48 kDa protein encoded by the IKBKG gene 
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located on the X-chromosome (Xq28) (23). In humans, a loss-of-function mutation results in the 
production of a truncated protein, leading to antenatal lethality in males and incontinentia 
pigmenti (IP) in females (17, 23, 24). Female patients exhibit dermatosis, ophthalmologic, 
odontologic and nervous system abnormalities (23). Female mice heterozygous for NEMO 
exhibit keratinocyte hyper-proliferation, inflammatory infiltration and apoptosis in skin, similar 
to the manifestations in human IP patients (24, 25). EAD-ID results from hypomorphic mutation 
of NEMO. Affected males are able to survive, but suffer from EDA-ID due to reduced NF-κB 
activation, exhibiting fewer sweat glands, sparse scalp hair, absent teeth and recurrent infections 
(17, 23).  
            Although the exact mechanisms by which the IKK complex gets activated remain elusive, 
accumulating evidence suggests that ubiquitination of NEMO by E3 ubiquitin ligases plays a 
pivotal role in transducing signals and recruiting the IKK complex to upstream activators, such 
as transforming growth factor-β (TGFβ)-activated kinase-1 (TAK1) and MAPK-ERK kinase 








Figure 2: Structures of IKK subunits.  Structural motifs of IKKα, IKKβ and NEMO are 
shown. CC, coiled-coil domain; LZ, leucine-zipper domain; HLH, helix-loop-helix domain; 
NBD, NEMO-binding domain; ZF, zinc-finger domain. (Figure adapted from Perkins N.D. 2007 
(3) ) 
1.1.4 IκB proteins 
NF-κB activation and inactivation are tightly controlled by a group of inhibitory proteins IκBs, 
which function to mask the conserved nuclear localization sequence (NLS) on RelA/p65 and 
sequester NF-κB heterodimers in the cytoplasm in inactive condition (3). Nine IκB proteins have 
been identified and are divided into four groups: typical IκB proteins (IκBα, IκBβ, and IκBε), 
precursor proteins (p100 and p105), atypical IκB proteins (IκBζ, IκBNS and BCL-3) and an 
alternative transcript of IκBα (IκBγ) (3, 29, 30). All IκBs are characterized by the presence of 
five to seven ankyrin repeats that interact with the RHD in NF-κB subunits to mask the NLS and 
prevent nuclear translocation (29). Typical IκB proteins usually are present in the cytoplasm in 
an inactive state and go through degradation and resynthesis upon stimulation, whereas atypical 
IκB proteins are inducibly expressed in stimulated cells (29). In inactive conditions, IκBα masks 
the NLS of p65, exposing nuclear export sequence (NES) in IκBα, and sequesters NF-κΒ 
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heterodimers in the cytoplasm (30). The degradation of IκBα disrupts this balance and favors the 
nuclear localization of NF-κB. To establish a new balance, cytoplasmic localization of IκBα-NF-
κB complexes is restored by NES in newly synthesized IκBα, which acts to shuttle NF-κB 
dimers back to the cytoplasm (30, 31) (Fig 3). 
 
 
Figure 3: Members of IκB family. Structural motifs of nine IκB proteins are shown. ANK, 
ankyrin-repeat motifs; PEST, domain rich in proline (P), glutamate (E), serine (S) and threonine 
(T); RHD, Rel-homology domain; GRR, glycine-rich region; DD, death domain. (Figure adapted 
from Perkins N.D. 2007 (3) ) 
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1.1.5 Activation of NF-κB 
A wide variety of stimuli can lead to the activation of NF-κB. Depending on the involvement of 
specific IKK components, NF-κB subunits and upstream activators, NF-κB activation is divided 
into the canonical pathway and non-canonical pathway (IKK complex-independent pathway). As 
a result, distinct subsets of target genes are transcriptionally regulated in respond to intracellular 
and extracellular stresses. 
1.1.5.1 Canonical NF-κB pathway   Extensive effort has been devoted to the characterization of 
the canonical NF-κB pathway during the past two decades. Various pro-inflammatory factors are 
able to activate NF-κB via binding to transmembrane receptors, such as tumor necrosis factor 
receptor (TNFR), interleukin-1 receptor (IL-1R), toll like receptor (TLR) and T-cell receptor 
(TCR) (32-34). All these distinct pathways eventually converge on activated IKK complexes, 
which induce phosphorylation of IκBα at Ser 32 and 36, followed by the polyubiquitination and 
degradation of IκBα in the 26S proteasome. The liberated NF-κB heterodimer then translocates 
into nuclei where it binds to the κB DNA response elements to regulate transcription (3) (Fig. 4). 
            In addition, genotoxic stress has been shown to induce the activation of NF-κB through a 
complex of ataxia telangiectasia mutated (ATM) and NEMO (3, 4). Nuclear DNA damage 
rapidly leads to the activation of the checkpoint kinase ATM, which in turn phosphorylates and 
facilitates the sumoylation and mono-ubiquitination of NEMO in the nucleus (3, 4). Mono-
ubiquitination of NEMO then leads to the nuclear export of ATM-NEMO complex to the 






Figure 4: The activation of canonical and non-canonical NF-κB pathways.  The canonical 
NF-κΒ pathway is induced by TNF-α, IL-1, LPS, TCR ligands and genotoxic stress. TNF-α-
induced NF-κB activation requires adaptor proteins, TRADD and TRAFs (also act as E3 
ubiquitin ligases), as well as RIP1, the polyubiquitination of which is required for the recruitment 
of IKK complexes to TAK1 kinase. TAK1 kinase is responsible for the phosphorylation of 
IKKβ, which in turn leads to the phosphorylation and degradation of IκBα. The liberated 
p65/p50 heterodimers then translocate into the nucleus regulating target gene expression. IL-1 
and LPS activate the canonical NF-κB pathway through IL-1R and TLR-4 respectively, resulting 
in the recruitment of MyD88, IRAK and TRAF6, which are essential for the activation of TAK1. 
Activated TAK1 then phosphorylates the IKK complex, leading to NF-κB activation. TCR 
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ligation induces an activation of the PKCθ kinase, which further activates the Carma1-Bcl-10-
Malt1 complex, leading to the activation of TAK1 via TRAF2/6. In response to DNA damage, 
activated ATM phosphorylates nuclear NEMO at Ser 85. Phosphorylated NEMO then undergoes 
sumoylation and monoubiquitination. Mono-ubiquitinated NEMO in turn translocates to the 
cytoplasm with ATM, activating the IKK complex and NF-κB. Notably, A20 and CYLD, both of 
which are de-ubiquitinating enzymes (DUBs), negatively regulate NF-κB activation by 
disassembling the K63-linked ubiquitin chains on NEMO. (Figures were adapted from (3, 29, 
32-35)) 
1.1.5.2 Non-canonical NF-κB pathway  The non-canonical NF-κB pathway is distinct given it 
is IKK complex-independent. Genetic evidence indicates an essential role of this pathway in 
lymphoid organogenesis, B-cell survival, dendritic cell activation, and osteoclastogenesis (36, 
37). The non-canonical pathway can be initiated by lymphotoxin beta (LTβ), B-cell activating 
factor (BAFF), CD40 and RANKL, which activate NF-κB-inducing kinase (NIK). NIK in turn 
activates the homodimeric IKKα complex, which results in the phosphorylation and proteasome-
dependent processing of p100 to p52. This is followed by the release of p52-RelB complex into 
the nucleus, which binds to specific κB elements (3).  
Another IKK complex-independent NF-κB pathway is mediated by tyrosine kinases and 
casein kinase-II (CK2) in response to oxidative stress (hypoxia and hydrogen peroxide), and 
genotoxic stress (UV) and oncogene HER2, respectively. These kinases directly phosphorylate 
IκBα, releasing p50-RelA dimers into nucleus where NF-κB exerts its transcriptional activity (3). 
 10 
1.1.6 NEMO-binding domain (NBD) peptide 
NEMO was identified in 1998 by Karin and Israel, who reported a direct and stable association 
of NEMO to IKKβ, but not to IKKα (38, 39). Further studies demonstrated an essential role of 
NEMO in the activation of the canonical NF-κB pathway induced by TNF-α, LPS and IL-1, by 
acting as a regulatory adaptor protein (20, 40). May et al. hypothesized that prevention of the 
association of NEMO and IKKs may inhibit NF-κB activation. They further demonstrated that 
this protein-protein interaction requires the C-terminus of IKKβ and the N-terminus of NEMO 
(41). They identified the α2-region in the C-terminus of IKKβ (IKKβ 735-745) as the NEMO-
binding domain (NBD), which contains six core amino acids (LDWSWL) that are conserved 
between IKKα and IKKβ (41). Site directed mutagenesis revealed an essential role of D738, 
W739 and W741 in mediating the binding of NEMO and IKKα/β, which was further confirmed 
by crystallography studies (11, 42). May and colleagues thus developed a cell-permeable peptide 
(FTALDWSWLQT), based on the eleven amino acids derived from the NEMO-binding domain 
in the C-terminus of IKKβ, termed NBD peptide (41). The peptide selectively inhibits the kinase 
activity of the IKK complex by disrupting the association between IKKβ and NEMO without 
affecting basal NF-κB activity (41). NBD peptide also blocks the association of NEMO and 
IKKα, although with a significantly lower affinity (18, 43-45). 
            Although kinase inhibitors targeting IKKβ strongly inhibit NF-κB activity in vitro, 
effects in vivo are less than optimal due to reasons unknown. In contrast, NBD peptide potently 
inhibits NF-κB in vivo and has therapeutic effects in various murine disease models. In 2004, 
Ghosh et al. showed that NBD peptide not only attenuated RANKL-mediated osteoclastogenesis 
but also reduced the severity of collagen-induced arthritis in vivo, suggesting that NBD peptide 
could be a clinical tool for the management of chronic joint swelling or destruction of bone and 
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cartilage (46). Plevy et al. in 2007 reported that the NBD peptide blocked LPS-mediated NF-κB 
activation in the mouse intestine and, more importantly, ameliorated established chronic colitis in 
IL-10-/- mice, by reducing the production of inflammatory cytokines by mucosal macrophages 
(47). In addition, Guttridge and colleagues showed a significant therapeutic effect of NBD 
peptide in mdx mice, a murine model of Duchenne muscular dystrophy (DMD). Macrophage-
mediated inflammation and necrosis were reduced and muscle regeneration were improved by 
chronic treatment of NBD peptide (48). The therapeutic effects of the NBD peptide were also 
established in murine models of Parkinson’s disease, Type 1 diabetes, as well as other diseases 
mediated by NF-κB activation (49, 50). Moreover, a phase 1 clinical trial testing the safety and 
efficacy of NBD peptide was conducted in a canine model of activated B-cell (ABC) diffuse 
large B-cell lymphoma (DLBCL), where increased apoptosis and a reduction in tumor burden 
were demonstrated post-treatment, indicating the possible utility of NBD peptide in clinical 
treatment (51). Additionally, another trial in the golder retriever muscular dystrophy (GRMD) 
model of DMD showed improved pelvic limb muscle force as well as attenuated histopathology 
(52). 
            Thus, the NBD peptide is of potentially great utility for clinical interventions for the 
following reasons: 1) strong inhibitory and therapeutic effects in various animal models across 
different species; 2) selective inhibition of IKK/NF-κB activation in response to stress without 
influencing its basal activity, which should minimize potential side effects, such as infection or 
immunosuppression; 3) inhibition of the IKK complex activity by disrupting the association 
between NEMO and IKKα/β, which should limit off-target effects, in particular limiting 
crossreaction with other kinases as kinase inhibitors do; and 4) ability to block established 
chronic NF-κB activation by disrupting the association of preformed IKK complexes. However, 
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one obstacle to the application of NBD peptide as a therapeutic is that the NBD peptide is 
technically difficult to synthesize, making it expensive to conduct clinical trials in human. Thus, 
developing small molecules mimicking the NBD peptide would be advantageous, which will be 
discussed in the following chapters. 
1.2 ATAXIA TELANGIECTASIA MUTATED (ATM) IN DNA DAMAGE RESPONSE  
1.2.1 Ataxia Telangiectasia mutated (ATM) 
Ataxia telangiectasia mutated (ATM) is a Serine/Threonine protein kinase that belongs to the 
phosphatidylinositol 3 kinase-like kinase (PIKK) family (53). Other PIKK Ser/Thr protein 
kinases include ataxia-telangiectasia and RAD3-related (ATR) and DNA-dependent protein 
kinase catalytic subunit (DNA-PKcs), both of which are also involved in the DNA damage 
response (53). ATM kinase is primarily activated by DNA double-strand breaks (DSBs) and 
functions to regulate cell-cycle checkpoints and DNA repair machinery to maintain genome 
stability. Patients deficient in ATM have increased radiosensitivity, chromosome aberrations and 
neurodegeneration (54). Inactive ATM resides in the nucleus as homodimers or higher-order 
multimers, which dissociate and obtain kinase activity upon autophosphorylation at Ser1981 (55, 
56). ATR is activated by single-stranded DNA damage that occurs during DNA replication and 
is recruited to preserve the stability of replication forks (57). DNA-PKcs, the catalytic subunit of 
DNA-PK, is indispensible for the non-homologous end-joining (NHEJ) repair of DSBs, where 
sequence homology is not required (58).  
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1.2.2 DNA damage response (DDR) 
DNA damage can be triggered by endogenous insults, including replication error and fork 
collapse, and exogenous genotoxins such as ultraviolet (UV), ionizing radiation and 
chemotherapeutic drugs (59). In response to double-strand breaks, MRE11-RAD50-NBS1 
(MRN) complex is recruited to the DNA lesion site to initiate the DNA damage response, which 
in turn attracts and activates ATM kinase (53, 56, 60). Activated ATM phosphorylates a histone 
H2A variant (γH2AX), which is a key step to amplify DDR signaling (53, 56, 60) (Fig. 4). 
γH2AX helps attract multiple DNA repair proteins, leading to the formation of detectable DNA 
damage foci. Another pivotal consequence of ATM activation is the engagement of cell cycle 
checkpoint kinase 2 (CHK2), which functions away from the lesion site (53, 56, 60). CHK2 
activation results in the activation of a tumor suppressor p53, which further leads to the 
transcription of a cyclin-dependent kinase inhibitor p21, thus initiating cell-cycle arrest (53, 56, 
60). Collectively, these processes are termed the DNA damage response (DDR). Cell-fate 
decisions are made depending on the extent and types of DNA damage. Mild DNA damage 
results in transient cell-cycle arrest and DNA damage foci will be eventually disassembled. In 
contrast, severe DNA damage may enhance DDR signaling, forming persistent, enlarged nuclear 
foci including γH2AX and 53BP1, which leads to permanent cell cycle arrest and cellular 
senescence. An additional outcome of extensive DNA damage is apoptosis (53, 56, 60). 
Similar to DSBs, single-strand DNA breaks, including those that occur at stalled 
replication forks, attract a different serine/threonine protein kinase, ATR to the lesion site. 
γH2AX is also a core component of this ATR-mediated DDR signaling. However, ATR recruits 
a different subset of DDR mediators, including replication protein A (RPA), heterotrimeric 9-1-1 
complex (RAD9-RAD1-HUS1) and topoisomerase-II-binding protein1 (TOPBP1) (57, 61-63). 
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To halt the cell cycle progression, checkpoint kinase 1 (CHK1) and downstream effector cell-
division cycle 25 (CDC25) phosphatases are modified, leading to a rapid cell-cycle arrest (57, 
61-63). 
1.2.3 Ataxia-telangiectasia (A-T): a rare autosomal recessive disorder 
Ataxia-telangiectasia (A-T) was first reported in 1926 by Syllaba and Henner and was described 
as a distinct syndrome by Boder and Sedgewick in 1957 (64, 65). A-T is a very rare autosomal 
recessive disease, caused predominantly by frameshift or nonsense mutations (80-90%) in ATM, 
which lead to a truncated form of ATM (53, 66, 67). A-T patients exhibit neurodegeneration, 
immunodeficiency, growth retardation, radiation sensitivity and cancer predisposition (68). A-T 
carriers, comprising around 1% of the general population, do not appear to have 
neurodegeneration or a cancer predisposition (69, 70). Mouse models of A-T, where no ATM 
protein is expressed, have been reported to recapitulate most human A-T symptoms, with the 
exception of progressive neurodegeneration (71). Interestingly, mice bearing a loss-of-function 
mutation of ATM (D2880A/N2885K, D2899A or Q2740P) exhibit disrupted kinase activity and 
are embryonic lethal, likely due to an enhanced inhibition on homologous recombination (72, 
73). Evidence also suggests that ATM inhibitors targeting the kinase domain can cause a more 
severe phenotype in cell culture than in ATM-null cells (74).  
1.2.4 Cytoplasmic function of ATM 
Increasing evidence indicates that ATM, in addition to its nuclear functions regulating DNA 
repair machinery, also plays an important role in the cytoplasm, revealing the long-time 
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unknown mechanisms underlying the metabolic syndrome and neurological pathology in A-T 
patients (75). Cytoplasmic functions of ATM have been identified in response to hypoxia, insulin 
and reactive oxygen species (ROS), unveiling its versatile roles as a protein kinase (76, 77). 
Emerging evidence has linked ATM to redox balance by suggesting that oxidative stress, in the 
absence of DSBs, could activate dimeric ATM in a manner independent of Mre11-Rad50-Nbs1 
(MRN) complex and ATM autophosphorylation (78). Recent studies further revealed that ATM 
negatively regulates the mTOR complex 1 (mTORC1), and thus promotes autophagy and limits 
cell growth in response to ROS (75, 79). Collectively, oxidative stress activates cytoplasmic 
ATM, which in turn induces the phosphorylation and activation of AMPK (AMP-activated 
protein kinase) at Thr172 through LKB1 (liver kinase B1). Activated AMPK subsequently 
activates the Tuberous sclerosis complex 2 (TSC2), which negatively regulates mTORC1 (53, 
75, 79). Further studies demonstrated that ATM-null cells have increased mitochondrial number 
due to impaired destruction (mitophagy), rather than increased mitochondrial biogenesis, linking 
ATM protein to mitophagy (53, 80). Additionally, a fraction of ATM protein has also been found 
in centrosomes, peroxisomes and vesicles (81-83).  
1.3 CELLULAR SENESCENCE AND AGING 
Aging refers to a state of gradual decline in physical activity and organ function over time. With 
progress in modern medicine over the past few decades, more people are living longer and aging 
is rapidly becoming an emerging problem that brings new challenges to the healthcare system as 
well as economy. The population aged 65 or older is projected to outnumber children under age 
5 in 2020 and reach 1.5 billion worldwide in 2050 (84) (Fig. 5). Thus a major shift of leading 
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diseases, from communicable to noncommunicable diseases, is expected, such as heart disease, 
hypertension, diabetes, cancer, lung disease and mobility impairment. The incidence of these 
chronic diseases increases exponentially with age, thus are termed aging-related diseases. As 
aging-associated diseases tend to occur in combination, understanding the underlying 
mechanisms of aging would be of great help to better prevent and manage frailty and 
comorbidities in the elderly. 
 
Figure 5: Global population older than 65 and under age 5. Data were collected by United 
Nations Department of Economic and Social Affairs, Population Division. (Reprinted from “why 
population aging matters: A global perspective” (84).) 
 
Senescent cells are metabolically active yet irreversiblely held in G1/G2 phase in 
response to intrinsic and extrinsic cellular stresses. Cellular senescence, in particular replicative 
senescence, was first described more than 50 years ago by Hayflick and Moorhead, who 
 17 
demonstrated that human cells in culture could undergo a finite number of cell divisions (85). 
Senescent cells are known to accumulate in mammals as they age (86) and are found to be 
associated with many age-related degenerative diseases, such as atherosclerosis, osteoarthritis, 
sarcopenia, gastrointestinal ulcers, and Alzheimer’s disease (87). Furthermore, cellular 
senescence facilitates tissue remodeling by promoting embryogenesis and wound healing (88). A 
recent study in transgenic mice clearly demonstrated that removal of even a fraction of senescent 
cells attenuates many age-related symptoms in mice with accelerated aging (89).  Moreover, a 
new class of drugs that induce apoptosis of senescent cells, termed senolytics, is able to enhance 
cardiovascular function in chronologically aged mice, restore treadmill endurance in radiation-
exposed mice, and decrease frailty, neurologic dysfunction and bone loss in progeroid mice (90). 
Thus cellular senescence is a physiologically important process in aging, a process that needs to 
be further studied in both animal models and in patients. 
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1.3.1 Senescence-inducing stimuli 
1.3.1.1 Telomere attrition  Telomere refers to the repetitive DNA sequences located at the 
termini of linear DNA in eukaryotic cells to protect end to end fusion of chromosomes (91). 
Telomerase functions to elongate the telomeric repeats on chromosomes. Telomere shortening 
occurs with each cell division, thus leading to a finite doubling capacity (replicative senescence) 
especially in human somatic cells, where telomerase activity is undetectable (91, 92). Human 
cells overexpressing telomerase exhibit reduced senescence as well as extended proliferative 
capacity (93). Telomere deficient mice exhibit premature aging similar to other progeria mouse 
models and the reintroduction of telomerase is able to attenuate tissue atrophy and stem cell 
depletion (94).  
The inability of the DNA replication machinery to copy the lagging ends of 
chromosomes directly leads to telomere shortening, which can be recognized as double-strand 
breaks by DNA repair proteins (95, 96). As a result, DDR proteins, including the tumor 
suppressor p53-binding protein 1 (53BP1), γH2AX, ATM, Mre11, Rad50, NBS1 and checkpoint 
kinase 2 (CHK2), are recruited to the telomeric DNA, forming telomere dysfunction-induced 
foci (TIFs), which triggers a cell-cycle arrest (95, 97). Notably, TIF-induced senescence can be 
attenuated by caffeine and wortmannin, which are ATM inhibitors, as well as in A-T cells where 
ATM is depleted, suggesting a requirement for persistent DDR signaling to maintain replicative 
senescence (95, 98).  
Telomere shortening-induced senescence is of great importance in human aging, as 
human somatic cells don’t express telomerase. Therefore, understanding telomere shortening-
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mediated senescence and aging will provide great insights into human aging development and 
progression. 
1.3.1.2 DNA damage-induced senescence  When DNA damage occurs, repairable DNA lesions 
will lead to a transient DDR response, while irreparable DNA damage will result in apoptosis or 
a sustained DDR signaling that eventually leads to cellular senescence. Persistent DNA damage 
response chronically activates p53 and p21, inducing and maintaining irreversible cell-cycle 
arrest. Additionally, persistent DNA damage signaling has been demonstrated to be 
indispensable for the senescence-associated secretory phenotype (99). ATM knockdown in vitro 
using shRNA/siRNA reduces cellular senescence and the production of IL-6, suggesting a 
central role of DDR signaling in senescence and SASP (99).  
1.3.1.3 Oncogene-induced senescence (OIS)  Oncogenic Ras provokes permanent G1 cell cycle 
arrest in primary cells, which is termed oncogene-induced senescence (100). Ras acts as a 
sustained mitogenic stimulus in cells, leading to aberrant DNA replication, which in turn results 
in the accumulation of DNA damage and persistent DDR signaling (101). The arrested cell 
growth in Ras-induced replicative senescence is achieved by engaging cell-cycle regulators 
p53/p21 and p16 (100). Notably, oncogene activation of E2F3 and c-Myc triggers cell growth 
arrest via a DDR-independent pathway (102, 103). BRAF(V600E), a dominant mutation in 
melanoma, induces senescence by upregulating mitochondrial pyruvate dehydrogenase (PDH), 
highlighting a role of bioenergetics in driving senescence (87). Of note, one common mechanism 
mediating OIS is the engagement of p53-p21 and/or p16INK4a-Rb to initiate and maintain cell 
cycle arrest. Similarly, inactivation of tumor suppressors, such as PTEN, Rb and NF1, also 
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induces senescence (104, 105). Oncogene-induced senescence prevents precancerous cells from 
unlimited proliferation, thereby has an important impact on combating tumorigenesis. Studying 
the underlying mechanisms of OIS will provide insights into the development of pro-senescence 
therapy for cancer treatment (104).  
1.3.1.4 Reactive oxygen species (ROS)  The free radical theory of aging was first raised in 1954 
by Harman, who postulated that free radical reactions that are largely of mitochondrial origin, 
drive aging (106). Moreover, it was predicted that antioxidants, caloric restriction and the 
reduction of temperature would elongate life expectancy, all of which proved correct 60 years 
later (106). Parrinello et al. demonstrated that primary mouse embryonic fibroblasts with long 
telomeres undergo cellular senescence in ambient oxygen (20%), possibly due to the increased 
oxidative damage. Senescence could be delayed by physiological oxygen tension (3%) and was 
later suggested to be associated with mitochondrial production of ROS  (107, 108). Furthermore, 
sublethal doses of hydrogen peroxide, endogenous superoxides and hydroxyl radicals are 
implicated in p53/p21-dependent G1 cell cycle arrest (109, 110). Notably, scavengers of free 
radicals, such as N-acetylcysteine (NAC), rescue p53 and/or p21 mediated growth arrest (111). 
Moreover, oncogene activation, such as Ras, increases mitochondrial mass, ROS and oxidative 
DNA damage in human fibroblasts, suggeting a central role of mitochondrial dysfunction in 
cellular senescence (108).  
Multiple causes of senescence, such as telomere shortening, oncogene activation and 
oxidative stress, induce DNA damage and persistent DDR signaling. Thus understanding the role 
of DDR signaling will greatly advance our understanding of cellular senescence. 
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1.3.2 Biomarkers of senescence 
Senescent cells exhibit cell markers that make them distinguishable from other cell populations, 
especially quiescent cells, which are arrested in G0 (59). Morphological changes, including a 
flattened and enlarged appearance, increased vacuolization and stress granules are observed in 
senescent cells in vitro.  
1.3.2.1 Senescence-associated β-galactosidase (SA-βgal)   Senescence-associated β-
galactosidase (SA-βgal) staining is one of the best-characterized and most convenient single-cell 
based methods to measure senescence in vitro and in vivo. SA-βgal staining measures the activity 
of lysosomal-origin β-galactosidase at a suboptimal pH of 6.0 instead of acidic pH of 4.0 (112). 
It was demonstrated that senescent cells exhibit increased lysosomal biogenesis which results in 
abundant lysosomal enzyme activity as well as increased lysosomal mass (113). Replicative 
senescence, genotoxic or oxidative stress-mediated senescence in vitro, as well as aged tissues 
such as skin, liver, kidney and pancreas, all stain blue by SA-βgal assays (114, 115). Notably, 
increased senescence-associated β-galactosidase activity is a consequence of senescence rather 
than its cause, as cells deficient in lysosomal β-gal still undergo senescence (116). Moreover, 
although SA-βgal is a biomarker of senescence, it hasn’t been connected with any specific 
pathways identified yet in senescent cells and is not required to reach the cellular senescent state 
(115).   
1.3.2.2 Tumor suppressors: p16Ink4a and p21CIP1  p16Ink4a, a G1 cyclin-dependent kinase 
(CDK) inhibitor targeting CDK4 and CDK6, negatively regulates the phosphorylation of 
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retinoblastoma protein (Rb), thus blocking cell-cycle progression from G1 to S phase. CDKN2A, 
also named the INK4a-ARF locus, encodes p16Ink4a as well as p14ARF (human) and p19ARF 
(mouse) proteins. p14ARF and p19ARF, which are translated in an alternative reading frame (ARF), 
are distinct tumor suppressors from p16INK4a (117-119). Evidence suggests that p14ARF stabilizes 
p53 by promoting the degradation of MDM2 (117-119). Deletion of the ARF-INK4a locus 
disrupts both tumor suppressor pathways: p16-Rb and p53-p19/p14.  
p16Ink4a is upregulated in senescent cells and aged tissues, but absent in healthy and 
young tissues. Inducible depletion of p16Ink4a positive cells reduces cellular senescence in tissues 
and extends the healthspan of BubR1H/H mice (120-122). In addition, increased expression of 
p19ARF has been linked to aging in rodent and human tissues, mirroring p16Ink4a (121). However, 
the exact role of p19ARF in senescence remains controversial. 
p21Cip1, encoded by CDKN1A (CIP1/WAF1), is another cyclin-dependent kinase 
inhibitor regulating cell cycle progression through G1-, G2- and S-phase (123). In response to 
DNA damage, p21 is upregulated transcriptionally by the tumor suppressor p53, which is a major 
effector in cellular senescence (124). p21Cip1 accumulates in senescent cells, which correlates 
with G1 phase cell-cycle arrest (125). Deletion of p21Cip1 improves the function of progenitor 
cells and hematopoietic stem cells in telomerase knockout mice, suggesting that telomere 
shortening-induced senescence is mediated by p53/p21 (126). Moreover, oncogenic activation of 
Ras can transcriptionally regulate p21Cip1 in a p53-independent way (127). 
            Cellular stress that induces the DNA damage response, primarily engages the p53/p21 
pathway via ATM/ATR kinase to halt cell-cycle progression, whereas certain oncogenic 
activation is associated with p16/Rb signaling. However, the two effector pathways likely 
converge in late phase of senescence through an undefined mechanism. 
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1.3.2.3 Loss of Lamin B1  In senescent cells, the overall nuclear morphology, including nuclear 
lamina, nucleoli, nuclear matrix and nuclear bodies, are altered and multi-nucleation can often be 
seen as a consequence of defects in nuclear envelope breakdown (128). Nuclear lamins 
contribute to the size, shape and stability of the nucleus and are divided into type A (A and C) or 
type B (B1 and B2). Several reports suggest that lamin B1 is a biomarker for senescent cells with 
loss of lamin B1 observed in senescent cells, but not in quiescent cells. Additionally, inhibition 
of lamin B1 drives proliferating cells to a senescent state. Downregulation of lamin B1 also leads 
to major chromatin remodeling, leading to senescence and the production of SASP.   
1.3.2.4 Senescence-associated secretory phenotype (SASP)  Senescent cells undergo 
widespread changes in protein expression and secretion, including the acquisition of the 
senescence-associated secretory phenotype (SASP) (87). Among more than 40 identified SASP 
factors are proteins involved in cellular signaling, such as growth factors (e.g. transforming 
growth factor-β (TGF-β)), inflammatory cytokines such as interleukins (IL-6) and chemokines 
(IL-8), and proteases (129). Senescence-activated transcription factors (such as NF-κB or 
C/EBPβ), DDR signaling molecules and certain microRNAs must be expressed to promote 
SASP (130, 131). SASP not only is a marker of senescent cells, but also can induce senescence 
through a non-cell autonomous mechanism (129, 132).  
1.3.3 NF-κB activation in cellular senescence and aging 
NF-κB pathway is a conserved signaling pathway that responds to multiple cellular stresses, 
including pro-inflammatory stress, oxidative stress and genotoxic stress, which are all implicated 
as factors in aging. NF-κB activity is elevated in numerous aged tissues, such as skin, cerebellum 
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and kidney (133-135). A genome-wide motif study by Adler et al. identified NF-κΒ as the most 
strongly activated transcription factor in natural aging in humans and mice, as well as premature 
aging in mice(136). Moreover, they reported that inducible genetic depletion of NF-κB 
rejuvenated aged skin and reverted the transcriptome of skin to that of younger mice (136).  
A causal role of NF-κB in cellular senescence and aging was established by 
pharmacologic and genetic reduction of NF-κB in two progeria mouse models. Our group 
demonstrated an elevated NF-κB level in multiple tissues in Ercc1-/Δ mice, a mouse model of 
XPF progeroid syndrome, including kidney, muscle, pancreas and liver (137). Reducing NF-κB 
activity genetically (p65+/-) or pharmacologically (NBD peptide) significantly ameliorated the 
aging symptoms as well as aging-associated pathology (137). Increased NF-κB activity was also 
reported in Zmpste24-/- mice, a model of Hutchinson-Gilford progeria syndrome (HGPS), where 
prelamin A is not processed properly to lamin A (138). RelA/p65 haploinsufficiency was shown 
to extend the lifespan and attenuate aging-associated pathology in skin, spleen and thymus in 
Zmpste24-/- mice (138). Notably, this study implied an activation of ATM and NEMO-dependent 
NF-κB pathway in response to nuclear lamina defects, which would indicate that ATM and 
NEMO may be essential mediators transducing signals from nuclear to cytoplasm (138). 
Interestingly, tissue specific knockout of IKKβ in brain and hypothalamic microglia ameliorates 
aging-associated neurodegeration and extends longevity by regulating gonadotropin-releasing 
hormone (GnRH) (139). This suggests that the hypothalamus plays a role in programming aging, 
in addition to its well known roles in growth, development and metabolism (139). NF-κB has 
also been linked to a variety of aging-related chronic diseases, such as Alzheimer’s disease, 
Parkinson’s disease, Type 2 diabetes, osteoporosis and atherosclerosis (140). 
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Increased chronic low-grade inflammation has been noted in Nfkb1/p50-/- mice, thus a 
premature aging phenotype in these mice would further back a causative role of NF-κB in 
driving aging (141, 142). Two recent studies showed that mice lacking the p50 subunit of NF-κB 
exhibited accelerated aging features such as kyphosis and osteoporosis, as well as significantly 
shortened lifespan, approximately around 90 weeks (141, 143). Furthermore, these results 
suggest chronic inflammation as an inducer of cellular senescence and premature aging (143).  
It is important to note that pro-inflammatory SASP factors produced by senescent cells 
are transcriptionally regulated by NF-κB. SASP factors relay stress signals in cell-intrinsic and 
cell-extrinsic fashions, to enhance cell cycle arrest, amplify the inflammatory cascade and alter 
the tissue microenvironment (144-147). The most prominent SASP components, IL-6 and TNFα, 
are implicated in cell-autonomous and cell-nonautonomous pathways to extend senescent signals 
to neighboring cells via transmembrane receptors, such as interleukin-1 receptor (IL-1R) and 
tumor necrosis factor receptor 1/2 (TNFR1/2) (129) (145). 
Notably, IKK and NF-κB-inducing kinase (NIK) protein levels are unchanged in tissues 
of old rodents where NF-κB nuclear-translocation is increased (148). Moreover, the 
transcriptional activity of a parallel pro-inflammatory pathway, activation protein 1 (AP-1), 
remains unchanged or even decreased in old livers (149). 
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1.4 Ercc1-/Δ PROGERIA MOUSE MODEL 
1.4.1 ERCC1-XPF endonuclease 
ERCC1 (excision repair cross-complementation group 1) forms a heterodimeric complex with 
XPF (xeroderma pigmentosum group F), acting as a structure-specific endonuclease essential for 
the repair of nucleotide excisions (NER), DNA interstrand crosslinks (ICLs) and double-strand 
breaks (DSBs) (150). XPF contains the nuclease activity and ERCC1 facilitates DNA binding 
and the stabilization of XPF (150, 151). Several inherited human diseases are linked to mutations 
in ERCC1-XPF, such as xeroderma pigmentosum (XP), cerebro-oculo-facioskeletal syndrome 
(COFS), Cockayne syndrome, Fanconi anemia and XFE progeroid syndrome (152). Only two 
cases of Ercc1 mutation in humans have been reported and were diagnosed with COFS 
syndrome and Cockayne syndrome respectively (153, 154). Most reported cases of XPF 
deficiency in human are characterized by UV sensitivity, freckling of skin and late-onset of skin 
cancer, as well as neurodegeneration and premature aging in very rare cases (150). Thus murine 
models deficient in ERCC1-XPF were generated to understand its biological role and the link to 
diverse syndromes associated with impaired DNA repair. Interestingly, evidence suggests that 
mouse models deficient in ERCC1 or XPF have identical phenotypes and both exhibit 
accelerated aging (155, 156) 
1.4.2 Ercc1 hypomorphic mice (Ercc1-/Δ) 
Ercc1 hypomorphic mice (Ercc1-/Δ), in which 5% of normal levels of ERCC1 is expressed, are 
considered a murine model of XPF progeroid syndrome. The normal lifespan of wild type mice 
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is around 3 years, while Ercc1-/Δ mice have a shorter lifespan of 7 months that allows a time 
window for phenotyping aging-associated symptoms as well as testing pharmacological 
interventions (157). Ercc1-/Δ mice are smaller in size compared to wild-type controls, but there is 
no evidence yet supporting developmental defects in Ercc1-/Δ mice (158, 159). Ercc1 
hypomorphic mice grow normally until 8 weeks, then gradually develop aging-associated 
phenotypes that progress rapidly (158, 159). Similar to Ercc1 mutation in human, Ercc1-/Δ mice 
exhibit severe neurological symptoms (ataxia, gait disorder and dystonia), kyphosis, tremor and 
muscle wasting, which resemble symptoms in old WT (158, 159). Notably, Ercc1 hypomorphic 
mice spontaneously develop numerous aging-associated diseases over time, including 
osteoporosis, intervertebral disc degeneration, sarcopenia, renal and liver dysfunction, 
neurodegeneration and muscle wasting (152, 160-163). 
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2.0  CELLULAR SENESCENCE IS INDUCED IN AN ATM-NF-κB-DEPENDENT   
MANNER IN A DNA DAMAGE-INDUCED PROGERIA MOUSE MODEL 
2.1 INTRODUCTION 
Aging, a process associated with accumulation of cellular senescence, loss of organ homeostasis 
and decline of stem cell function, has been implicated in various aging-related diseases, 
including osteoporosis, intervertebral disc degeneration, liver and kidney dysfunction, diabetes, 
neurodegeneration and cancer (164). Cellular senescence, characterized by cell cycle arrest, has 
been demonstrated to cause aging-related phenotype, based on the finding that depletion of 
p16INK4a positive cells in BubR1H/H progeroid mice led to an extended healthspan (122). 
Senescent cells produce a distinct group of secretion factors, including cytokines, chemokines, 
growth factors and proteases, termed senescence-associated secretory phenotype (SASP) (129, 
132). Pro-inflammatory SASP components, such as IL-6, IL-1α and TNF-α, were shown to 
extend senescence to neighboring cells by transducing stress signals in both cell-autonomous and 
cell-nonautonomous fashions (129, 165, 166).  
DNA damage response (DDR) is a critical pathway required for faithful replication and 
genome stability by recruiting and forming a multiprotein complex at the site of DNA double-
strand breaks (DSBs) (78, 167-169). Ataxia-telangiectasia mutated (ATM) kinase is a central 
mediator required for the initiation and amplification of DDR signaling. Upon DNA damage, the 
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MRE11-RAD50-NBS1 (MRN) complex is recruited to the lesion sites as the first sensor, which 
in turn facilitates the recruitment, retention and activation of nuclear ATM (53). 
Autophosphorylated ATM kinase subsequently leads to the phosphorylation and activation of a 
histone H2A variant (γH2AX), which acts to further amplify DDR cascade by attracting more 
ATM protein, as well as recruiting more DDR effectors to the DNA lesions. Multiple DDR 
proteins, such as KRAB-associated protein-1 (KAP1), p53 and checkpoint kinase 2 (CHK2), are 
phosphorylated by ATM kinase once recruited, which further promotes cell-cycle arrest, DNA 
repair, apoptosis or senescence (61, 170).  
 The nuclear factor κB (NF-κB) family of transcription factors consists of five members 
in mammalian cells, including RelA/p65, RelB, c-Rel, p50/p105 and p52/p100. All NF-κB 
proteins contain a Rel-homology domain (RHD), which is essential for DNA binding activity 
and dimerization. NF-κB functions to regulate innate and adaptive immune responses, 
development, proliferation, apoptosis, oncogenesis and senescence (3). The canonical NF-κB 
pathway is activated by inflammatory stimuli, such as TNF-α, IL-1α, IL-1β and LPS, which 
activate the IκB kinase (IKK) complex. The IKK complex in turn phosphorylates and facilitates 
the degradation of the inhibitory protein IκBα in 26S proteosome, which leads to the release of 
NF-κB dimers into the nucleus where it can regulate the transcription of target genes (3). The 
IKK complex is composed of two catalytic subunits, IKKα and IKKβ, and one regulatory 
subunit, NF-κB essential modifier (NEMO/IKKγ). Miyamoto et al. demonstrated a role for 
genotoxic stress in the activation of TNF-α-independent NF-κB pathway, which is absent in 
ataxia-telangiectasia (AT) cells (4, 171). Upon DNA damage, activated ATM mediates a series 
of post-translational modifications on NEMO, including phosphorylation at Ser85 and 
sumoylation and mono-ubiquitination at Lys 277 and 309 (172). This in turns triggers the nuclear 
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export of ATM-NEMO complex to the cytoplasm, where it converges on the IKK complex to 
initiate NF-κB activation (4).  
Elevated NF-κB activity has been found in multiple aged tissues, such as skin, 
cerebellum and kidney (133-135). Mounting evidence suggests that NF-κB activation plays a 
causal role in cellular senescence and aging (137, 138, 146). This is supported by our previous 
study that genetic reduction of the RelA/p65 subunit of NF-κB delayed the onset of aging 
symptoms in Ercc1-/Δ mice (137). In addition, Zmpste24-/- mice heterozygous for p65/RelA 
exhibited attenuated aging pathology and a prolonged lifespan, which was linked to a reduced 
systemic inflammatory response and a reduction in ATM- and NEMO-mediated NF-κB 
activation (138). Moreover, Nfkb1-/- mice, where increased low-grade inflammation was noted, 
showed signs of premature aging, exhibited by neural degeneration, impaired regeneration and 
declined overall lifespan (141, 143, 173, 174). In addition, NF-κB was associated with multiple 
aging-related chronic diseases, including Alzheimer’s disease, Parkinson’s disease, Type II 
diabetes, osteoporosis and atherosclerosis (140). This could be largely attributed to the systemic 
inflammation mediated by chronic NF-κB activation (175). Moreover, NF-κB is considered as a 
master regulator of SASP factors, which can be transcriptional regulated by NF-κB. 
Persistent DDR signaling mediated by accumulative DNA damage, particularly ATM 
activation, has been demonstrated to be essential for cellular senescence and the SASP 
phenotype (99). Genotoxic stress induced by DNA damage, oxidative stress, telomere shortening 
or oncogene activation, could trigger an upregulation of p53/p21 pathway, leading to cell-cycle 
arrest. Senescence that developed independent of DNA damage, such as p16Ink4a overexpression, 
was also shown to trigger cell growth arrest, but failed to induce the secretion of SASP 
components due to the lack the persistent DNA damage response (87, 99, 176). Moreover, a 
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previous study reported unresolved DNA damage foci and elevated ATM at the transcriptional 
level in ap2-Ercc1F/- mice, where a DNA repair protein was specifically knocked out in adipose 
tissue, again implicating a central role of ATM and DDR in aging (177). However, it remains 
elusive whether ATM or DDR signaling plays a causal role in senescence and aging. 
Here we used an Ercc1-/Δ mouse model, where only 5% of ERCC1-XPF was expressed, 
to address the causal role of DDR signaling in senescence and aging. The Ercc1 hypomorphic 
(Ercc1-/Δ) mice exhibit defects in nucleotide excision repair, interstrand crosslink repair and DSB 
repair, and spontaneously develop osteoporosis, sarcopenia, intervertebral disc degeneration, 
glomerulonephropathy, neurodegeneration, peripheral neuropathy, incontinence and loss of 
vision, hearing and cognition. We found that NF-κB level was persistently elevated in both 
chronological and accelerated aging, concomitant with a hyperactive DDR signaling. Repressing 
ATM in the presence of persistent DNA lesions reduced cellular senescence and downregulated 
ATM- and NEMO-mediated NF-κB activation in vitro. Ercc1-/Δ mice heterozygous for Atm 
exhibited significantly reduced NF-κΒ activity, as well as extended healthspan. Our findings 
suggest that the DSB-mediated DDR response, especially ATM kinase activation, may directly 
lead to NF-κB activation through NEMO shuttling, resulting in intensified senescence and aging. 
Furthermore, we showed that the reduction of ATM activity could attenuate a premature aging 
phenotype, suggesting ATM as a potential therapeutic target for delaying or improving frailty 
and aging-related diseases. 
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2.2 MATERIALS AND METHODS 
2.2.1 Cells and mice   
Primary mouse embryonic fibroblasts (MEFs) were isolated on embryonic day 12.5-13.5. In 
brief, mouse embryos were isolated from yolk sac followed by complete removal of viscera, lung 
and heart. Embryos were then minced into fine chunks, fed with MEFs medium, cultured under 
3% oxygen to reduce stresses and split till confluence. MEFs were grown in 1:1 of Dulbecco’s 
Modification of Eagles Medium (with 4.5g/L glucose and L-glutamine) and Ham’s F10 medium, 
supplemented with 10% fetal bovine serum, penicillin, streptomycin and non-essential amino 
acid. To induce oxidative stress-induced DNA damage in Ercc1-/- MEFs, MEFs were transferred 
to 20% oxygen for further incubation starting from passage 3. 
Ercc1+/- and Ercc1+/Δ mice from C57BL/6J and FVB/n backgrounds were crossed to 
generate Ercc1-/Δ F1 hybrid mice to prevent potential strain-specific pathology. Atm+/- mice were 
crossed to Ercc1+/- from C57BL/6J background to generate Atm+/-;Ercc1+/- mice, which were 
then bred with Ercc1+/Δ mice from FVB/n background to generate Atm+/-;Ercc1-/Δ mice. Mice 
were backcrossed for 10 generations to achieve genetic identity. Animal protocols used in this 
study were approved by Scripps Florida Institutional Animal Care and Use Committees. 
2.2.2 Immunoblotting   
MEFs were treated with KU-55933 (Selleckchem) or vehicle control for 72 hours. Cells lysate 
were prepared in RIPA buffer (20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM Na2EDTA, 1 
mM EGTA, 1% NP-40, 1% sodium deoxycholate, 2.5 mM sodium pyrophosphate, 1 mM β-
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glycerophosphate, 1 mM Na3VO4, 1 µg/ml leupeptin, 1X protease inhibitor cocktails (sigma) and 
1X Halt phosphatase inhibitor cocktail (Thermo)). Snap frozen liver and kidney were 
homogenized in RIPA buffer described above using FastPrep-24 instrument. 40-50 ug protein 
was resolved by MINI-PROTEAN TGX 4-15% SDS-PAGE. Blots were blocked in 5% non-fat 
milk. Primary antibodies were incubated at 4oC overnight and secondary antibodies were 
incubated at room temperature for 1 hour. Anti-p-ATM (1:1000, Rockland), anti-ATM (1:1000 
CST), anti p-KAP1 (1:1000 Abcam), anti-KAP1 (1:2000 Abcam), anti-γ-H2AX (1:5000 Novus), 
and anti-PARP1 (1:1000 CST) were employed to detect DDR proteins.  Anti-p-p65 (1:1000 
CST), anti-p65 (1:2000 CST), anti-p-IκBα (1:1000 CST), anti-IκBα (1:2000 CST) and anti-
NEMO (1:1000, CST) were used to assess NF-κB activation. Anti-p16 (1:1000, Santa Cruz) and 
anti-p21 (1:1000 Santa Cruz) were used to detect the expression of senescent markers. Anti-
laminA/C (1:5000 Santa Cruz), anti-tubulin (1:2000 CST), anti-GAPDH (1:5000 CST) and anti-
actin (1:5000 Santa Cruz) were used as loading controls. 
2.2.3 Nuclear extraction  
Cytoplasmic and nuclear fractions were extracted using the NE-PER nuclear and cytoplasmic 
extraction reagents (ThermoFisher) according to the manufacturer’s instructions. Briefly, 1x106 
cells were suspended and lysed in CERI and CERII reagents consecutively on ice. The 
supernatant of centrifugation was collected as cytoplasmic fraction, and the pellet was suspended 
in NER reagent and collected as nuclear fraction. 
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2.2.4 Quantitative reverse transcription-polymerase chain reaction  
Snap frozen tissues were preserved in RNAlater RNA stabilization solution (ThermoFisher). 
Total RNA was extracted using TRIZOL reagent  (Life Technologies) and 1.5 μg of RNA was 
subjected to synthesize complementary DNA (cDNA) using SuperScript VILO cDNA synthesis 
kit. qRT-PCR was performed in a StepOnePlus Real-Time PCR system using Platinum SYBR 
Green qPCR SuperMix-UDG (ThermoFisher). Target gene expression was calculated using the 
comparative CT method (ΔΔCT) and normalized to an internal control gene Actb (β-actin). 
Primers used are as follows: Cdkn1a (p21) forward: GTCAGGCTGGTCTGCCTCCG; Cdkn1a 
(p21) reverse: CGGTCCCGTGGACAGTGAGCAG; Cdkn2a (p16) forward: 
CCCAACGCCCCGAACT; Cdkn2a (p16) reverse: GCAGAAGAGCTGCTACGTGAA; Tnf  
(TNF) forward: CTATGTCTCAGCCTCTTCTC; Tnf  (TNF) reverse: 
CATTTGGGAACTTCTCATCC; Il6 (IL-6) forward: AAGAAATGATGGATGCTACC; Il6 (IL-
6) reverse: GAGTTTCTGTATCTCTCTGAAG; Actb (β-actin) forward: 
GATGTATGAAGGCTTTGGTC; Actb (β-actin) reverse: TGTGCACTTTTATTGGTCTC. 
2.2.5 Immunofluorescent staining 
MEFs were seeded onto chamber slides and allowed to attach in 20% oxygen overnight. Cells 
were fixed in 4% paraformaldehyde (PFA) for 10 min, permeabilized with 0.3% Triton X-100 
and blocked with 3% BSA for 1 hour in room temperature. Primary antibody incubation was 
performed overnight at 4oC and secondary antibody incubation for 1 hour at room temperature. 
Cell nuclei were counterstained with Vectashield mounting medium with DAPI. Five images of 
 35 
each cell type were acquired using an Olympus confocal microscopy at 40x magnification. 
Primary antibodies used are as follows: anti-p65 (Santa Cruz) and anti-NEMO (Santa Cruz). 
2.2.6 Senescence-associated β-galactosidase staining in vivo and in vitro  
MEFs were seeded into a 6-well plate at 3x104 cells per well, allowed to attach overnight and 
treated by vehicle control or KU-55933 at 10 uM for 72 hours. Cells and fresh fat tissues were 
fixed in 2% formaldehyde and 0.2% glutaraldehyde in PBS for 10 minutes and then stained with 
SA-βgal staining (pH 5.8 for MEFs and pH 6.0 for fat) solution (40 mM citric acid in sodium 
phosphate buffer, 5 mM K4[Fe(CN)6] 3H2O, 5 mM K3[Fe(CN)6], 150 mM sodium chloride, 2 
mM magnesium chloride and 1 mg/ml X-gal dissolved in N,N-dimethylformamide) for 16-20 
hours in a 37oC incubator without CO2 injector. To quantify, ten images were acquired randomly 
using a bright-field microscopy at 20x maginification. Total SA-βgal+ cells was normalized to 
the total cell number (DAPI). Fresh liver tissues were fixed in 10% neutral buffered formalin 
(NBF) for 3-4 hours and then transfered to 30% sucrosed overnight to replace water. Tissues 
were then imbeded in OCT and stored at -80oC. Cryosection at 5μM was performed and slides 
were stained in SA-βgal staining solution (pH 5.8) at 37oC for 16-24 hours. To quantify, ten 
random images were captured using a bright-field microscopy at 20x magnification and the 
number of SA-βgal+ cells was counted. The quantification was shown as mean+/- SD. 
2.2.7 Health Evaluation  
Health assessment was conducted weekly to assess body weight, general conditions, 
neurodegeneration and muscle wasting. Kyphosis, body condition and coat condition were 
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assessed as general conditions. Ataxia, dystonia, gait disorder and tremor are used as indicators 
for neurodegeneration. Muscle wasting was studies by evaluating hindlimb paralysis and 
forelimb grip strength. All aging symptoms were scored based on a scale of 0, 0.5 and 1, except 
dystonia with a scale from 0 to 5. The sum of aging scores for each genotype group was used to 
determine the overall aging conditions. 
2.2.8 Cell proliferation assay 
Passage 3 MEFs were seeded in a 10-cm plate at 5x105 cells and allowed to grow for 72-96 hours 
in 20% oxygen. Cells were then trypsinized. Harvested cells were counted using a Moxi Z Mini 
automated cell counter and then seeded at the same density until passage 5. Log cell number was 
plotted versus each passage. 
2.2.9 Histology analysis  
Tissues fixed in 10% neutral buffered formalin (NBF) overnight were imbedded in paraffin. 
Tissue was sectioned at 5 μm using a microtome. Hematoxylin and eosin (H&E) staining was 
conducted following a standard protocol. 
2.2.10 Glycosaminoglycan (GAG) analysis 
Snap frozen lumber spines were harvested from 12-week-old Ercc1-/Δ and Atm+/-;Ercc1-/Δ mice. 
Nucleus pulposus (NP) tissue was isolated under microscope and six lumbar intervertebral discs 
were pooled together for analysis. GAG was isolated by papain digestion at 60oC for 2 hr. GAG 
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concentration was measured by following DMB procedure (Sigma) and DNA concentration was 
measured using PicoGreen assay (Molecular Probes), which was used for normalization. 
2.2.11 Statistical analysis 
All values were presented as mean+/-S.E.M. Microsoft Excel and Graphpad Prism 6 were used 
for statistical analysis. Two-tailed Student’s t-test was performed to determine differences 
between two groups. When comparing difference in more than two groups, one-way ANOVA 
(Dunnett test) was conducted. A value of p <0.05 was considered as statistically significant, 
shown as *p <0.05, **p <0.01, and ***p < 0.001. 
2.3 RESULTS      
2.3.1 NF-κB and DDR signaling are highly activated in cellular senescence and in 
accelerated and natural aging 
Multiple age-related chronic diseases, including Type 2 diabetes, osteoporosis, disc degeneration 
and cancer, are associated with elevated NF-κB activity (140). Blockade of NF-κB activity in 
epidermis in chronologically aged transgenic mice rejuvenated skin aging, suggesting that NF-
κB may be one of the driving forces in aging. Our previous study demonstrated an increased NF-
κB activation in the liver, kidney, skeletal muscle and pancreas of Ercc1-/Δ mice by using an NF-
κBEGFP knock-in mouse model. Here we found that the level of p-p65 (Ser 536) was increased in 
the liver of 16-week-old Ercc1-/Δ mice, while wild type (WT) mice at the same age only showed 
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a minimal activation (Fig. 6A). To determine if NF-κB hyperactivation correlates with DNA 
damage-induced DDR signaling, we measured the total expression of ATM and its downstream 
substrates. In Ercc1-/Δ liver, we also found elevated level of p21 protein, which is a main 
downstream effector of p53 and a biomarker of senescence (Fig. 6B). The level of γH2AX, a 
substrate of ATM and a marker of senescence reflecting persistent DNA damage, was also 
increased, consistent with our previous findings that Ercc1-/Δ mouse liver bear more oxidative 
DNA damage than WT littermates (Fig. 6B) (137). Old mice have more irreparable DSBs in 
liver, kidney, lung, brain and testes, as measured by γH2AX foci, compared to young animals 
(178). Thus to test if Ercc1-/Δ mice mirror natural aging, we tested liver from WT mice at 
different ages. Higher p-p65 level was detected in 2-year-old WT livers (with lifespan of 3 years) 
compared to livers from 3 and 12 months old animals where only minimal p65 activation was 
observed (Fig6. C&D). Consistently, activation of IκBα was slightly increased in 2-year-old 
liver, as represented by p-IκBα. We then tested primary mouse embryonic fibroblasts (MEFs) 
isolated from Ercc1-/- embryos, where no ERCC1-XPF was expressed. We discovered a higher 
level of p-p65 in passage 5 Ercc1-/- MEFs grown at ambient oxygen levels (20%), compared to 
WT MEFs (Fig. 6F). Phosphorylation of ATM and KAP1, an ATM effector, were increased in 
Ercc1-/- MEFs compared to WT MEFs (Fig 6E). Immunofluorescent staining of p65 and NEMO 
in Ercc1-/- and WT MEFs revealed increased nuclear-localized p65 and NEMO, suggesting 
upregulated p65 activation (Fig 6G). Although NEMO is mainly a cytoplasmic protein, its 
shuttling between nucleus and cytoplasm has been shown required for bridging ATM and NF-κB 
upon genotoxic stress (4). Taken together, our results suggest an activation of NF-κB pathway in 




Figure 6: DDR and NF-κB are activated simultaneously in senescent MEFs, Ercc1-/Δ and 
old WT mice. (A) Western blots of p-p65 (Ser536) and p65 were performed with liver lysate 
from 16-week-old WT (n=3) and Ercc1-/Δ (n=3) mice. GAPDH was used as an internal loading 
control. (B) Immunoblot analysis was performed against DDR proteins, including ATM, γH2AX 
and p21, with liver lysate from 16-week-old WT and Ercc1-/Δ mice. (C) Levels of p-p65 were 
measured with liver tissues from 3, 12, 24 months old WT mice. n=3 mice per group. (D) The 
levels of p-IκΒα (Ser 32/36) and IκΒα were measured by western blot with liver tissues from 6, 
12, 24 months old WT mice. (E) Primary MEFs were cultured in 20% oxygen to induce 
oxidative stress-induced senescence. Immunoblotting for DDR activation was performed with 
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nuclear extract from passage 5 senescent MEFs. (F) Whole cell lysates of passage 5 MEFs were 
immunoblotted for p-p65 and total p65. (G) Passage 4 MEFs were sub-cultured for 24 hrs and 
cytoplasmic and nuclear localized p65 (green) and NEMO (green) were detected by 
immunofluorescent staining. Nuclei were counterstained with DAPI (blue). Representative 
images were taken at the magnification of 40x. 
2.3.2 Pharmacologic inhibition of ATM rescues oxidative stress-induced senescence by 
suppressing ATM- and NEMO-dependent NF-κB activation 
To further elucidate the causative role of DDR signaling, specifically ATM kinase, in driving 
senescence, we employed a selective ATM kinase inhibitor, KU-55933 (179). To mimic 
physiological conditions, ambient oxygen tension (20%) was used to induce endogenous DNA 
damage in primary WT and Ercc1-/- MEFs. Ercc1-/- MEFs exhibited increased SA-βgal positive 
staining with serial passaging at 20% oxygen, and maximal cellular senescence was observed at 
passage 5 represented by enlarged and flat morphology as well as increased SA-βgal staining 
(Fig. 7A) (137). KU-55933 remarkably reduced SA-βgal staining in senescent Ercc1-/- MEFs to a 
level similar to WT MEFs (Fig. 7A&B). Additional senescent markers, tumor suppressors p21 
and p16, were also decreased by the treatment of KU-55933, confirming reduced cellular 
senescence by the inhibition of ATM (Fig. 7C). As expected, ATM activation, as indicated by 
autophosphorylation at Ser1981, was downregulated by KU-55933 (Fig. 7D). Moreover, p-
KAP1 and γH2AX were found at lower levels after the treatment (Fig. 7E). Poly [ADP-ribose] 
polymerase 1 (PARP1) has been shown to participate in DNA repair and chromatin remodeling 
by consuming NAD+, the depletion of which has been linked to mitochondrial dysfunction 
observed in neurodegeneration and aging. Interestingly, ATM inhibition for 72 hr was able to 
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decrease the level of PARP1, suggesting that the suppression of primary DDR signaling may 
have a broader effect (Fig. 7D). Notably, the treatment with ATM inhibitor also decreased p65 
activity, as represented by reduced level of p-p65 and less nuclear-translocated p65 and NEMO, 
detected by western blot (Fig. 7F&G). Taken together, DNA damage plays an essential role in 
driving senescence and the inhibition of DDR signaling not only reverses cellular senescence, 
but also inhibits NF-κB activation in an ATM- and NEMO-dependent manner.  
 
 
Figure 7: Pharmacologic inhibition of ATM rescues oxidative stress-induced senescence by 
suppressing ATM- and NEMO-dependent NF-κB activation. (A) Passage 5 primary WT and 
Ercc1-/- MEFs were cultured in 20% oxygen in the presence of ATM inhibitor (10 μM of KU-
55933) or vehicle for 72 hr. Senescent cells were detected by SA-βgal staining shown in blue. 
Representative images were obtained at the magnification of 10x. (B) Quantitation showed the 
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average percentage of SA-βgal positive cells from 3 independent experiments. (C) Passage 5 
primary Ercc1-/- MEFs were treated with 10 μM of KU-55933 for 72 hours. Whole cell lysate 
and nuclear extract were prepared for western blot analysis. Immunoblot for senescent markers 
p16 and p21 (C) and DNA damage sensors p-ATM, ATM and PARP1 (D) were performed with 
whole cell lysate. (E) Nuclear extract were blotted for ATM substrates, p-KAP1, KAP-1 and 
γH2AX. LaminA/C was used as a loading control. (F) The levels of nuclear translocated NEMO 
and p65 were determined by western blot using nuclear extract. (G) The levels of p-p65 and total 
p65 were detected by immunoblot with the whole cell lysate. 
2.3.3 Deletion of one allel of Atm decreases oxidative stress-induced cellular senescence 
To rule out potential off-target effects of KU-55933, Ercc1-/- MEFs missing one allele of Atm 
(Atm+/-;Ercc1-/-) were generated. Proliferation assays comparing the growth of WT, Ercc1-/-, and 
Atm+/-;Ercc1-/- MEFs revealed an arrested population doubling in Ercc1-/- MEFs from passage 4 
to passage 5, which was partialy restored in Atm+/-;Ercc1-/- MEFs (Fig. 8A). SA-βgal staining 
also showed reduced senescent cells in Atm+/-;Ercc1-/- MEFs at each indicated passage compared 
to Ercc1-/- MEFs (Fig. 8B&C). In addition, immunoblot analysis showed decreased expression of 
p16Ink4a in Atm+/-;Ercc1-/- MEFs (Fig. 8D). Taken together, our results suggest that both 
pharmacologic and genetic reduction of ATM could successfully reverse oxidative stress-





Figure 8: Oxidative stress-induced cellular senescence is reduced in Atm+/-;Ercc1-/- MEFs. 
(A) Cellular proliferation was determined in passage 3, 4 and 5 WT (purple), Ercc1-/- (red) and 
Atm+/-;Ercc1-/- MEFs cultivated in 20% oxygen. (B) Primary MEFs were cultured in 20% 
oxygen at indicated passages for 72 hr and SA-βgal staining was conducted to quantify blue 
positive cells. Representative images were taken at the magnification of 10x. (C) The 
quantification of the average percentage of SA-βgal positive cells was plotted at each passage. 
(D) Passage 5 WT, Ercc1-/- and Atm+/-;Ercc1-/- MEFs was cultured in 20% oxygen for 72 hr and 
lysed for immunoblot analysis. The level of p16 was determined relative to GAPDH. 
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2.3.4 Atm haploinsufficiency reduces DDR signaling and NF-κB activation in Ercc1-/Δ 
mice 
To determine if DDR signaling indeed mediates NF-κB activation in aging, Ercc1-/Δ mice 
heterozygous for Atm were generated, showing dampened DDR activation. Livers from 16-
week-old WT, Ercc1-/Δ, and Atm+/-;Ercc1-/Δ mice were analyzed by western blot. We found 
markedly downregulated DDR signaling in Atm+/-; Ercc1-/Δ mice compared to Ercc1-/Δ mice, as 
indicated by lower levels of total ATM, p-KAP1 and γH2AX (Fig. 9A). Reduced p21 was found 
in Atm+/-; Ercc1-/Δ livers suggesting decreased cellular senescence (Fig. 9A). Intriguingly, 
phospho-p65 was also reduced to WT level in Atm+/-;Ercc1-/Δ mice, suggesting NF-κB activation 
in DNA damage-induced premature aging is mainly caused by ATM activation (Fig. 9B). 
Similarly, we found lower level of total IκBα in both WT and Atm+/-; Ercc1-/Δ mice compared to 
Ercc1-/Δ mice, again suggesting that activated ATM in Ercc1-/Δ mice may lead to increased NF-
κB transcriptional activity leading to increased synthesis of IκBα (Fig. 9B). This is consistent 
with previous finding that p65+/- MEFs express less total IκBα and IκBβ proteins compared to 
WT MEFs, and p65-/- MEFs contain only 35% of IκBα and almost no IκBβ (180, 181). To 
determine if Atm+/-; Ercc1-/Δ mice mirror molecular changes in p65+/-;Ercc1-/Δ mice, western blot 
analysis was performed to determine NF-κB activation and DDR signaling in Ercc1-/Δ and p65+/-
; Ercc1-/Δ mice. We found reduced p-p65 and total IκBα in p65+/-;Ercc1-/Δ livers, suggesting 
reduced NF-κB activation in p65+/-;Ercc1-/Δ liver (Fig. 9C). However, γH2AX level was found to 
be unaffected, confirming that DDR signaling is the upstream of NF-κB. Taken together, the 
results suggest that DDR signaling plays an essential role in NF-κB activation in DNA damage-
induced premature aging. Moreover, the deletion of one ATM allele is sufficient to downregulate 
 45 





Figure 9: NF-κB activation and DDR signaling are downregulated in Ercc1-/Δ mice 
heterozygous for Atm. (A) 16-week-old livers from WT (n=3), Ercc1-/Δ (n=3) and Atm+/-;Ercc1-
/Δ (n=3) were collected for western blot analysis and the levels of DDR proteins were blotted, 
including ATM, γH2AX, and p21. (B) The levels of p-p65, p65 and total IκBα were determined 
by immunoblot. Tubulin was used as a loading control. (C) 14-week-old livers from Ercc1-/Δ 
(n=3) and p65+/-;Ercc1-/Δ (n=4) were analyzed for the levels of NF-κB activation and DDR 
signaling by western blot. 
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2.3.5 Genetic reduction of Atm extends healthspan and alleviates progeroid symptoms by 
reducing cellular senescence 
We previously reported that genetic reduction of the RelA/p65 subunit of NF-κB could delay the 
onset of aging symptoms in Ercc1-/Δ mice, where chronic accumulation of DNA damage is the 
major driving force of aging symptoms. We hypothesized that Atm heterozygosity could 
phenocopy p65 haploinsufficiency and alleviate aging symptoms. Aging-related symptoms, 
including dystonia, kyphosis, tremor, ataxia, gait disorder, hindlimb paralysis and forelimb grip 
strength, were assessed weekly to closely monitor the onset, severity and progression of aging 
symptoms in Ercc1-/Δ mice. Total symptom score was used to evaluate the general health 
condition of mice. Ercc1-/Δ mice showed a gradual progression of aging symptoms exacerbating 
greatly at 12 weeks old, whereas Atm+/-; Ercc1-/Δ mice had less severe symptoms at younger 
ages, as well as slower progression of aging symptoms (Fig. 10A). A major neurological 
symptom that progresses rapidly in Ercc1-/Δ mice is dystonia (hindlimb clasping), which also 
occurs in neurodegenerative diseases such as Parkinson’s disease (PD) (182). The severity and 
exacerbation of dystonia were slowed in Atm haploinsufficent mice, indicating attenuated 
neurodegeneration (Fig. 10B). We also found reduced SA-βgal staining in adipose tissue, 
indicating less senescent adipocytes in Atm+/-; Ercc1-/Δ mice, consistent with qRT-PCR analysis 
showing reduced transcription of p16Ink4a and p21 (Fig. 10C&D).  





Figure 10: Atm+/-;Ercc1-/Δ mice exhibit attenuated aging phenotype and reduced cellular 
senescence. (A) Aging symptoms were assessed weekly on Ercc1-/Δ and Atm+/-;Ercc1-/Δ mice. 
The total score of aging symptoms was calculated and plotted at indicated ages. Representative 
pictures show the general health condition, body size and kyphosis of a pair of littermate at 15 
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weeks of age.  n=8-10 mice per group. (B) Dystonia was assessed and the score was plotted in 
bar graph. (C) SA-βgal staining of parametrial fat from 12-week-old Ercc1-/Δ and Atm+/-;Ercc1-/Δ 
mice. (D) Adipose tissue from 12-week-old WT, Ercc1-/Δ and Atm+/-;Ercc1-/Δ mice was analyzed 
for p16INK4a and p21 expression by qRT-PCR. n=3-4 mice each group.  
 
Consitent with these data, IL-6 and TNFα, the major SASP factors and NF-κB target 
genes, were downregulated in Atm+/-;Ercc1-/Δ liver compared to Ercc1-/Δ mice, in particular a 
significant reduction in IL-6 (Fig. 11A). p21 expression was also significantly reduced in Atm+/-
;Ercc1-/Δ liver, while no significant reduction was observed in p16 transcription, suggesting 
decreased p53/p21 and unaffected p16/Rb activity in Atm+/-; Ercc1-/Δ mice (Fig. 11A). Declined 
kidney function has been demonstrated in aged humans and mice, reflected by decreased 
glomerular filtration rate (GFR), accompanied by the increase in p16INK4a, p21 and SASP 
proteins. Our previous study found elevated NF-κB-eGFP expression in renal cortex, which led 
us to study molecular changes in kidney by qRT-PCR (137). However, we only found trends 
toward reduced IL-6 and p21 in Atm+/-; Ercc1-/Δ kidney, likely due to the rapid loss of senescent 
population in renal cortex, which was supported by our observation of decreased cortical 
thickness in Ercc1-/Δ kidney (Fig. 11B). Consistent with the western blot analysis, p65+/-;Ercc1-/Δ 
livers displayed significantly reduced IL-6 and TNF-α expression, but with p21 and p16 
remaining unaltered (Fig. 11C). Taken together, genetic reduction of ATM kinase led to an 
delayed aging symptoms as well as reduced cellular senescence in vivo. Moreover, our data 





Figure 11: Cellular senescence is reduced in Atm+/-;Ercc1-/Δ mice. Livers (A) and kidneys (B) 
from 12-week-old WT, Ercc1-/Δ and Atm+/-;Ercc1-/Δ mice were analyzed for the expression of 
p16, p21, IL-6 and TNF-α by qRT-PCR analysis. n=4-6 per group. (C) Livers from 14-week-old 
WT, Ercc1-/Δ and p65+/-;Ercc1-/Δ mice were analyzed for p16, p21, IL-6 and TNFα expression by 
qRT-PCR. n=4-5 per group. 
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2.3.6 Atm haploinsufficiency improves aging-related pathology in tissues 
Aging-associated kidney function decline has been noted for decades (183). Aged kidney is 
characterized by distinct pathological changes, including loss of cortical mass, as well as 
increased hyalinization, glomerular sclerosis, tubular atrophy and interstitial fibrosis (183). 
Histological analysis by H&E staining indicated attenuated glomerular sclerosis and tubular 
atrophy in Atm+/-;Ercc1-/Δ mice, compared to Ercc1-/Δ mice alone (Fig. 12A). In addition, decline 
of stem cell function has long been associated with aging (164, 184). We previously reported that 
muscle-derived stem/progenitor cells (MDSPCs) isolated from Ercc1-/Δ mice failed to proliferate 
or differentiate properly. Increased number of myocytes with central nuclei was found in Atm+/-
;Ercc1-/Δ mice, suggesting an increased capacity of muscle regeneration in vivo (Fig. 12B) (160). 
Osteoporosis and intervertebral disc degeneration are major degenerative changes that deteriorate 
progressively with aging. Glycosaminoglycan (GAG), a major proteoglycan in nucleus pulposus 
(NP) of the disc, is critical in protecting spines from mechanical compressive force and decreases 
significantly with aging (185). The loss of GAGs also leads to lower back pain and shortened 
spinal height. Surprisingly, although the disc is an avascular structure, Atm+/-;Ercc1-/Δ mice 
showed higher levels of GAGs in lumbar spines, consitant with Safranin O staining where 
proteoglycan was stained red, in comparison to Ercc1-/Δ mice (Fig. 12C) (186-188). Micro 
Computed Tomography (CT) analysis of lumber spines demonstrated an alleviated osteoporosis 
in Atm+/-;Ercc1-/Δ mice compared to Ercc1-/Δ mice (Fig. 12D). Additionally, oral glucose 
tolerance test (OGTT) showed that Atm+/-;Ercc1-/Δ mice clear glucose given by oral gavage more 
rapidly than Ercc1-/Δ mice (Fig. 12E). Taken together, our results suggest that herterozygosity of 




Figure 12: Genetic reduction of Atm improves aging pathology in progeroid Ercc1-/Δ mice. 
(A) H&E staining of kidney from 12-week-old Ercc1-/Δ and Atm+/-;Ercc1-/Δ mice. Representative 
images of renal cortex were taken at the magnification of 20x. n=2-3 per group. (B) Muscle 
sections were stained with trichrome to assess the number of myocytes with central nuclei. n=3 
each group. (C) Safranin O staining of thoracic discs from 12-week-old Ercc1-/Δ and Atm+/-
;Ercc1-/Δ mice. GAG levels from NP isolated from lumber discs were analyzed. n=3 each group. 
(D) Representative images of Micro CT analysis of lumber discs from 12-week-old WT, Ercc1-/Δ 
and Atm+/-;Ercc1-/Δ mice. (E) OGTT analysis performed in 10-week-old Ercc1-/Δ and 
Atm+/;Ercc1-/Δ mice. Blood glucose was measured at 0, 5, 15, 30, 60 and 90 min post dosing of 
glucose by oral gavage. 
2.4 DISCUSSION 
The accumulation of DNA lesions has long been considered a critical factor in cellular 
senescence and aging (96). Human progeroid diseases are closely related to inherited defects in 
maintaining genome integrity, such as xeroderma pimentosum, Cockayne syndrome, Fanconi 
anemia and Werner’s syndrome (152, 189). Moreover, a recent study indicates that genetic and 
pharmacologic reduction of ATM could attenuate mutant Huntingtin toxicity in vivo and in vitro, 
where increased levels of γH2AX have been implicated (70). Although there is increasing 
evidence suggesting that ATM kinase is a central mediator of DSB-induced cellular senescence, 
most studies were done in vitro by using inhibitors or RNA interference (RNAi) of ATM (99). 
Thus, in vivo evidence supporting a causal role of ATM in senescence and aging is still lacking 
and poorly documented. In this study, we demonstrated that genetic reduction of Atm in vivo was 
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able to extend healthspan, attenuate aging-related pathology as well as reduce cellular 
senescence in a mouse model of progeria, strongly supporting a causative role of ATM in aging. 
In our study, Atm haploinsufficiency showed substantially reduced NF-κB activation to a 
similar extent to p65 heterozygosity in Ercc1-/Δ mice, indicating that ATM kinase is a major 
activator of NF-κB in the context of DNA-damage mediated senescence and aging. In addition, 
significant downregulation of SASP factors, especially IL-6 at mRNA level, was discovered in 
both Atm+/-;Ercc1-/Δ and p65+/-;Ercc1-/Δ mice. These findings support previous studies reporting 
that ATM activation and perisistent DDR signaling are required for the SASP phenotype, 
secreting inflammatory cytokines (62, 99). Notably, p65 heterozygosity exhibited a stronger 
inhibition on IL-6 and TNF-α expression compared to Atm heterozygosity, suggesting the 
existence of an ATM-independent parallel pathway. A previous study suggested that extensive 
DSBs could lead to an ATM- and NEMO-dependent primary activation of NF-κB which induces 
the production of TNF-α (190). TNF-α in turn, via RIP1, triggers a second wave of NF-κB 
activation, as well as JNK3/AP-1 pathway (190). Thus we speculate that Atm haploinsufficiency 
only dampens the primary activation of NF-κΒ, while p65 heterozygosity targets both primary 
and secondary NF-κB activation, conferring a stronger inhibition of the SASP phenotype.  
Persistent DNA damage-mediated DDR signaling, in particular ATM activation, has been 
demonstrated to be essential for the SASP phenotype in vitro. However, mediators bridging 
ATM with SASP factors are still poorly identified (99). Miyamoto et al. previously revealed a 
novel NF-κB pathway in response to genotoxic stress, which requires the involvement of a 
nuclear translocated ATM-NEMO complex (4). In line with this, Osorio et al. reported increased 
ATM phosphorylation and nuclear-localized NEMO in Zmpste24-/- mice, where accumulated 
prelamin A led to a perturbation of NF-κB signaling, suggesting the involvement of an ATM- 
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and NEMO-dependent NF-κB pathway (138). However, recently a novel mechanism was raised 
by Kang et al. revealing that GATA4 might be one of the central mediators connecting DDR 
signaling to NF-κB, and further leading to the senescent SASP phenotype (191). In our study, we 
observed increased nuclear localization of NEMO in Ercc1-/- MEFs, which could be ablated by 
ATM inhibitor. This finding supports an activation of ATM- and NEMO-dependent NF-κB 
pathway in response to chronic DNA damage. However, simultaneous involvement of GATA4 
cannot be excluded without further testing of TRAF3IP2 and GATA4.  
Chronic low-grade inflammation locally and systemically has been linked to aging and 
multiple aging-related diseases, highlighting a pathological role of NF-κB activation, which 
transcriptionally regulates most inflammatory mediators (175). In addition, SASP factors 
secreted by senescent cells lead to an elevation of circulating pro-inflammatory cytokines, which 
further promotes many manifestations of aging-related pathology, such as sarcopenia, muscle 
wasting and insulin resistance (175, 192). Elevated levels of IL-6 and TNF-α have been observed 
in numerous aging-related diseases (175, 193). Anti-inflammatory treatments, such as 
nonsteroidal anti-inflammtory drug (NSAID), resveratrol, aspirin and metformin, have been 
suggested to improve frailty (194-197). Moreover, caloric restriction (CR), which is the most 
robust non-genetic anti-aging intervention across species, and physical exercise, have been 
shown to suppress chronic systemic inflammation (175, 198, 199). In line with these studies, we 
found significantly attenuated kidney pathology, improved stem cell function and alleviated disc 
degeneration, supporting a pathological role of NF-κB in aging-related diseases. 
Although Atm+/-;Ercc1-/Δ mice phenocopy p65+/-;Ercc1-/Δ mice in many aspects of aging 
molecularly and phenotypically, interestingly we found significant reduction of p21 expression 
only in Atm+/-;Ercc1-/Δ mice. This is consistent with current evidence that ATM/ATR-mediated 
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DDR signaling is responsible for the activation of p53/p21 pathway, leading to a CDK2-
dependent cell cycle arrest in G1 (200). However, whether ATM/ATR directly activates the 
p16/Rb pathway remains unknown. Our results showed no significant downregulation of p16 
expression in Atm+/-;Ercc1-/Δ mice, while p21 expression was dramatically reduced by 50%.  
This evidence is in agreement with previous studies that ATM activation regulates p53/p21 in 
aging. In addition, our finding suggests no direct regulation of p16/Rb by ATM or DDR 
signaling. SASP factors have been linked to the regulation of senescence and aging through 
unknown mechanisms. Conditional medium from senescent cells was demonstrated to induce 
secondary senescence in cell culture (165). An observation that senescent hepatocytes clustered 
together in mouse livers also confirmed a paracrine effect mediated by SASP factors (165, 166). 
It has been previously reported that conditional medium from senescent cells induced a full 
senescence response, including the activation of p16 and p21 and elevated levels of DNA 
damage (165, 166). However, our data showed no reduction in γH2AX level or p16 and p21 
expression in p65+/-;Ercc1-/Δ mice. Thus it is plausible that NF-κB-mediated SASP factors do not  
directly upregulate p53/p21 and p16/Rb pathways in senescence and aging. 
Increasing evidence indicates that ATM, in addition to its nuclear functions regulating 
DNA repair machinery, also plays important roles in the cytoplasm (75). Previous studies 
indicated a cytoplasmic function of ATM that negatively regulated the mammalian target of 
rapamycin complex1 (mTORC1) via tuberous sclerosis complex 2 (TSC2), thus promoting 
autophagy and suppressing cell growth in response to ROS (53, 75, 79). In addition, a small 
fraction of ATM has been identified in mitochondria, linking ATM to aberrant mitophagy (53, 
78, 80). Thereby it would be of great importance to characterize the impact of ATM reduction on 
mTORC1 signaling in response to ROS, given that oxidative stress is a major culprit of aging. 
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More importantly caloric restriction (CR) and rapamycin treatment inhibiting mTORC1 have 
been demonstrated to robustly prolong lifespan (201).  
Our results suggest that ATM acts as the main stimulus of NF-κB activation in DNA 
damaged-induced senescence and aging. Genetic reduction of Atm could extend healthspan, 
reduce cellular senescence as well as alleviate aging-related pathology, suggesting a causal role 
of ATM activation/DDR in aging. Our study also supports an activation of  genotoxic stress-
mediated NF-κB pathway in Ercc1-/Δ mice which is ATM- and NEMO-dependent. Taken 
together, our results suggest that ATM/NF-κB may be potential therapeutic targets for improving 
frailty and aging-related diseases.  
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3.0  DEVELOPMENT OF NOVEL NEMO-BINDING DOMAIN MIMETICS FOR 
INHIBITING IKK/NF-κB ACTIVATION 
3.1 INTRODUCTION 
Nuclear factor κB (NF-κB) is a transciption factor important for regulating immune responses, 
cell proliferation, apoptosis, embryonic development, senescence and cancer (3). In mammalian 
cells, NF-κB family is comprised of five subunits, RelA/p65, RelB, C-Rel, p50 (p105/NF-κB1) 
and p52 (p100/NF-κB2), all containing a Rel-homology domain (RHD) required for homo- or 
hetero-dimerizaiton (3). NF-κB dimers are sequestered in the cytoplasm by an inhibitory protein 
IκBα, which masks the conserved nuclear localization sequence (NLS) on RelA/p65 to prevent 
nuclear translocation (3). Upon stimulation, IκΒα undergoes phosphorylation, polyubiquitination 
and proteasome-mediated degradation, and eventually releases the NF-κB dimers to the nucleus 
(3). Nuclear-translocated NF-κB dimers up- or down-regulates target gene expression by binding 
to the κB enhancer or promoter elements (3). Inducers of NF-κB activity include pro-
inflammatory cytokines, including tumor necrosis factor α (TNF-α), interleukin-1 (IL-1), 
lipopolysaccharide (LPS), T-cell receptor (TCR) ligands and genotoxic and oxidative stress (3).  
 NF-κB activation is regulated by the IκB kinase (IKK) complex, comprised of two 
identified catalytic subunits, IKKα and IKKβ, and a regulatory subunit NEMO/IKKγ (10, 20, 
38). The domains in IKKα and IKKβ, required for the assembly of IKK complexes by facilitating 
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association with the α-helical region in N-terminus of NEMO, reside in the C-termini (11). An 
11 amino acid peptide derived from the NEMO binding domain (NBD) of IKKβ, amino acids 
735-745, is able to disrupt the association of IKKβ and NEMO and reduced NF-kB activation 
when fused to a protein transduction domain (PTD) for intracellular delivery (11).  
Duchenne muscular dystrophy (DMD) is an X-linked recessive inherited disease caused 
by the deficiency of dystrophin (202). Respiratory and cardiac failures are the primary causes of 
death in DMD patients in their 20’s due to progressive muscle wasting (203). Dystrophic muscle 
is characterized by necrosis, inflammatory infiltration, muscle degeneration and fibrosis (203). A 
role of NF-κB dysregulation in the pathogenesis of muscle dystrophy is previously established 
via p65 haploinsufficiency and conditional deletion of IKKβ, both of which improved the 
muscular pathology and muscle function (48, 204). It is becoming clear that the persistent 
secondary inflammation and extensive necrosis mediated by NF-κB cause the consecutive 
degeneration and regeneration cycles in satellite cells, which eventually lead to an exhaustion of 
their regenerating capacity and the irreversible muscle dystrophy (203). Thus, alleviation of NF-
κB-mediated chronic inflammation prevents the exhaustion of satellite cells and substantially 
improves the outcome of this genetic disease. 
LPS stimulates the canonical NF-κB pathway through toll-like receptor 4 (TLR4) via the 
adaptor protein myeloid differentiation primary response gene 88 (MyD88), regulating the 
production of various inflammatory cytokines and chemokines (205). The systemic endotoxemia 
induced by acute LPS administration can lead to multiple organ failure, in particular acute lung 
injury (ALI) (206). ALI is mainly characterized by lung edema and impaired pulmonary 
function, which are mediated by neutrophil infiltration and a pro-inflammatory response. The 
elevation of pro-inflammatory mediators, adhesion molecules, inducible nitric oxide synthase 
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(iNOS) and cyclooxygenase-2 (COX-2) occurs rapidly as early as 1hr, and maintains for 4 to 6 
hour post LPS administration (207, 208). Thus, this model was employed in our study to 
determine the inhibitory effects of NBD mimetics in an acute inflammatory model. 
The NBD peptide has strong therapeutic effects in various inflammatory disease models 
in mice and other species. Chronic, systemic administration of NBD peptide attenuates 
macrophage-mediated muscle necrosis and degeneration in mdx mice, a murine model of 
Duchenne muscular dystrophy (DMD) (48, 209), as well as in the golden retriever muscular 
dystrophy (GRMD) canine model of DMD (52).  Similarly, the NBD peptide ameliorates active 
chronic colitis in IL-10-deficient mice without affecting NF-κB basal activity when administered 
systemically (47). Intra-articular injection of NBD peptide also attenuates synovial inflammation 
and the severity of arthritis in a rat model of adjuvant arthritis (210). It also ameliorates 
inflammation-induced osteoclastogenesis and arthritis by downregulating NF-κB target genes, 
TNF-α and IL-1β (211). Moreover, systemic delivery of the NBD peptide reduces the severity of 
Parkinson’s disease by suppressing nigral microglial activation and reducing dopaminergic 
neuronal loss as well as alleviates nephropathy and atherosclerosis in Type 1 diabetic mice (46, 
49, 212). In addition, the peptide prevents an LPS-induced pulmonary inflammation in sheep and 
improves pulmonary function in a piglet model of acute respiratory distress syndrome by topical 
administration (213, 214). Also, clinical testing of the NBD peptide for local treatment of canine 
diffuse large B-cell lymphoma revealed a reduction in the proliferation of malignant B cells (51).  
Despite these strong and varied therapeutic effects of PTD-NBD peptides in animal 
models, the expense of peptide synthesis, the short half-life of the peptide and its lack of oral 
bioavailability limit its clinical use.  Thus the goal of this study was to develop small molecules 
that mimic the NBD peptide, targeting the NEMO binding domain of IKKβ to disrupt its binding 
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to NEMO. An in silico screen for structural similarity was conducted using a pharmacophore 
model based on the crystal structure of IKK complexes to identify novel NBD mimetics (42). 
Following multiple round of optimization, several compounds were demonstrated to significantly 
inhibit LPS- and TNFα-induced NF-κB activation by disrupting the association between IKKβ 
and NEMO. In addition, these compounds exhibited potent therapeutic effects in murine models 
of LPS-induced endotoxemia and Duchenne muscular dystrophy, suggesting their potential as 
therapeutic drugs for clinical management of diseases driven by IKK/NF-κB activation. 
3.2 METHODS 
3.2.1 Cells and mice   
HEK293 cells were grown in Dulbecco’s Modification of Eagles Medium (with 4.5g/L glucose 
and L-glutamine), supplemented with 10% fetal bovine serum, penicillin and streptomycin. 
Raw264.7 cells were cultured in RPMI-1640 media containing 10% heat-inactivated fetal bovine 
serum, penicillin and streptomycin. C57BL/10ScSn-Dmdmdx/J and female C57BL/6 mice were 
purchased form the Jackson Laboratory. Mice were housed in the animal facilities of Scripps 
Florida under constant temperature and humidity. Animal protocols used in this study were 
approved by Scripps Florida Institutional Animal Care and Use Committees. Three week-old 
sex-matched mdx mice were dosed with SR12343 (30 mg/kg), SR1246 (30 mg/kg), 8K-NBD 
peptide (10 mg/kg) or vehicle by intraperitoneal (i.p.) injection 3 times per week for 4 weeks. 
Mice were sacrificed at 7 weeks of age by carbon dioxide inhalation and tibialis anterior was 
collected for histological analysis. 
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3.2.2 8K-NBD peptide and small molecules  
8K-NBD (KKKKKKKKGGTALDWSWLQTE) peptide was synthesized at the peptide core 
facility of University of Pittsburgh. For i.p. injections, peptide was dissolved in 10% DMSO in 
PBS. The SR small molecules were designed and synthesized by Dr. Kamenecka lab at Scripps 
Florida. They were formulated in 10:10:80 of DMSO:Tween 80:Water for in vivo administration. 
ZINC small molecules were purchased from. All stock solutions for in vitro experiments were 
prepared in DMSO at 40 μM. 
3.2.3 LPS-induced acute lung inflammation  
LPS (strain O111:B4) was prepared in PBS at a sub-lethal dose of 10 mg/kg. 8-10 weeks old 
female WT mice (20-30 g) were dosed i.p. with vehicle, NBD peptide (10 mg/kg) or small 
molecules (10 mg/kg) for 30 min and followed by i.p. injection of saline (1 ml/kg) or LPS (10 
mg/kg). Mice were euthanized 2-4 hr post-treatment and lung was collected for further analysis.  
3.2.4 Functional grip strength analysis  
Seven week-old treated or untreated mdx mice were measured for forelimb grip strength using a 
digital grip strength meter paired with a metal grid (Bioseb). Mice were allowed to grip the metal 
grid tightly and readings were obtained by gently pulling the tail backward until release. Five 
sequential measurements were performed and the average force was calculated.  
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3.2.5 Firefly luciferase assay   
HEK293 cells stably transfected with luciferase reporter plasmid driven by NF-κB were seeded 
in 96-well plate in triplicate and pretreated with DMSO or varying small molecules at indicated 
concentration for 30 min, followed by the stimulation of 10 ng/ml of TNFα for 3 hr. Cell were 
washed with PBS once and harvested in passive lysis buffer. Luciferase assay (Promega) was 
performed using a luminometer according to the manufacturer’s instructions.  
3.2.6 Dual-luciferase reporter assay   
Blank HEK293 cells grown in 10 cm plates were co-transfected with co-reporter of Renilla 
plasmid driven by SV40 and luciferase plasmid driven by NF-κB at the ratio of 1:3 with 
Lipofectamine 2000 (Invitrogen). Transiently transfected HEK293 were grown and treated as 
described above and subjected to a dual-luciferase reporter assay according to the manufacturer’s 
instruction. Firefly luciferase activity was normalized to Renilla luciferase to get the relative 
luciferase activity. 
3.2.7 MTT assay   
HEK293 cells were grown in a 96-well plate at 3 x 104 cells/well in triplicate and treated with 
DMSO or varying small molecules at indicated concentration for 24 hr. Cell survival was 
determined by adding 20 ul of 5 mg/ml MTT (thiazolyl blue tetrazolium bromide) to each well 
followed by incubation for 3hr in an 37oC incubator. Media was removed and purple formazan 
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was dissolved in 100 ul of DMSO. Absorbance was measured at 590 nm on a microplate reader 
(Perkin Elmer). Cell viability was calculated by normalizing values to untreated control. 
3.2.8 Western blot   
HEK293 cells grown in a 6-well plate at 1 x 106 cells/well were left untreated or treated with 100 
μM of ZINC12909780 or ZINC3369392 for 30 min, followed by 10 ng/ml of TNFα for 0, 5 and 
10 min. Cells were then harvested for western blot. Cell lysate was prepared in RIPA buffer (20 
mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% NP-40, 1% sodium 
deoxycholate, 2.5 mM sodium pyrophosphate, 1 mM beta-glycerophosphate, 1 mM Na3VO4, 1 
µg/ml leupeptin, 1X protease inhibitor cocktails (sigma) and 1X Halt phosphatase inhibitor 
cocktail (Thermo)). 30 ug of protein was resolved by MINI-PROTEAN TGX 4-15% SDS-
PAGE. Blots were blocked in 5% non-fat milk. Primary antibodies were incubated at 4oC 
overnight and secondary antibodies were incubated at room temperature for 1 hour. Anti-p-IκBα 
(1:1000 CST) and anti-IκBα (1:2000 CST) were used to assess NF-κB activation. Anti-GAPDH 
(1:5000 CST) was used as a loading control. 
3.2.9 Immunoprecipitation of endogenous IKKβ and NEMO  
HEK293 or Raw264.7 cells were seeded at 1 x 106 cells/well in 6-well plates and treated with 
vehicle, small molecule or NBD peptide for indicated time. Cells were lysed in NP-40 lysis 
buffer supplemented with 1X protease inhibitor cocktails (sigma). Protein was 
immunoprecipitated by incubating 150 μg of lysate with 1 μg of anti-NEMO antibody (Santa 
Cruz) on a rotating shaker at 4oC for 4 hrs, followed by incubation with 20 ul of Protein A 
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agarose beads (ThermoFisher) for 1hr. Beads were washed in NP40 buffer 3 times and PBS 
once. Protein was then denatured in SDS-sample buffer and resolved by MINI-PROTEAN TGX 
4-15% SDS-PAGE. Anti-IKKβ (1:1000 CST) was used to assess binding of IKKβ to NEMO and 
anti-NEMO (1:1000 CST) or IgG were used to as a loading control.  
3.2.10 Electrophoretic mobility shift assay (EMSA)  
Cytoplasmic and nuclear fractions were extracted using the NE-PER nuclear and cytoplasmic 
extraction reagents (ThermoFisher) according to the manufacturer’s instructions. The gel shift 
assay was performed by following the previously described method (215). In brief, 5 μg of 
nuclear extract was incubated with gel shift binding buffer and an a-32P-deoxycytodine 
triphosphate–radiolabeled NF-κB probe for 20 min at room temperature (MP Biomedicals). The 
oligonucleotide sequences are as follows: NF-κB template, 5′-
CAGGGCTGGGGATTCCCCATCTCCACAGTTTCACTTC-3′; NF-κB annealing, 5′-
GAAGTGAAACTGTGG-3′. The reaction product was separated on a 6% non-denaturing 
polyacrylamide gel.  
3.2.11 Quantitative reverse transcription-polymerase chain reaction    
Snap frozen tissues were preserved in RNAlater RNA stabilization solution (ThermoFisher) 
before processed. Total RNA was extracted from cells or tissues using TRIZOL reagent (Life 
Technologies) and 1500 ng of messenger RNA (mRNA) was subjected to synthesize 
complementary DNA (cDNA) using SuperScript VILO cDNA synthesis kit. qRT-PCR was 
performed in a StepOnePlus Real-Time PCR system using Platinum SYBR Green qPCR 
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SuperMix-UDG (ThermoFisher). Target gene expression was calculated using the comparative 
CT method (ΔΔCT) and normalized to an internal control gene Actb (β-actin). Primers used are as 
follows: Ptgs2 (COX-2) forward: ACTCATAGGAGAGACTATCAAG; Ptgs2 (COX-2) reverse: 
GAGTGTGTTGAATTCAGAGG; Nfkbia (IκBα) forward: CAGAATTCACAGAGGATGAG; 
Nfkbia (IκBα) reverse: CATTCTTTTTGCCACTTTCC; Il1b (IL-1β) forward: 
GGATGATGATGATAACCTGC; Il1b (IL-1β) reverse: CATGGAGAATATCACTTGTTGG; 
Nos2 (iNOS) forward: TGAAATCCCTCCTGATCTTG; Nos2 (iNOS) reverse: 
CCATGTACCAACCATTGAAG; Tnf  (TNF) forward: CTATGTCTCAGCCTCTTCTC; Tnf  
(TNF) reverse: CATTTGGGAACTTCTCATCC; Il6 (IL-6) forward: 
AAGAAATGATGGATGCTACC; Il6 (IL-6) reverse: GAGTTTCTGTATCTCTCTGAAG. Actb 
(β-actin) forward: GATGTATGAAGGCTTTGGTC; Actb (β-actin) reverse: 
TGTGCACTTTTATTGGTCTC; 
3.2.12 Enzyme-linked immunosorbent assay (ELISA)   
Raw264.7 cells were grown in a 96-well plate and pretreated with vehicle, IKKi VII (2 uM) and 
small molecules (at indicated concentration) for 1hr, followed by the stimulation with 1 ug/ml of 
LPS. Supernatant was collected 24 hr later for ELISA analysis. IL-6 concentration was measured 
using a mouse IL-6 ELISA kit (BD) according to the manufacturer’s instructions. 
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3.2.13 Hematoxylin and eosin (H&E) staining   
Tissues fixed in 10% neutral buffered formalin (NBF) overnight were imbedded in paraffin. 
Tissue was sectioned at 5 μm using a microtome. H&E staining was conducted following a 
standard protocol (REF). 
3.2.14 Pharmacokinetics study 
The pharmacokinetic profile of the NBD Mimetics was determined in male C57BL/6J mice 
(n=3). The drugs were formulated in 10:10:80 of DMSO:Tween 80:water and were dosed by 
intraperitoneal injection at a final dose of 10 mg/kg. Blood, brain, muscle, spleen, and liver were 
collected 2 hr post-treatment and were analyzed by mass spectrometry by following the protocol 
described in ref. 215 (216). 
3.2.15 Pharmacophore Model Generation  
X-ray structure of the complex NEMO/IKKβ retrieved from the Protein Data Bank [PDB ID: 
3BRV], was used to generate a structure-based pharmacophore model (42). The three-
dimensional (3D) pharmacophore model was created with LigandScout (217, 218) and was 
based on interactions that define the protein-protein interaction, such as hydrophobic 
interactions, hydrogen bonding, and electrostatic interactions. Features identified by the 
LigandScout software are those that take into consideration chemical functionality but not strict 
structural topology or definite functional groups. As a result, completely new potential 
pharmacons can be identified through database screening. Moreover, to increase the selectivity, 
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the LigandScout model includes spatial information regarding areas inaccessible to any potential 
ligand, thus reflecting possible steric restrictions. In particular, excluded volume spheres placed 
in positions that are sterically not allowed are automatically added to the generated 
pharmacophore model. In this way, the structure-derived pharmacophore model contains the 
pharmacophore elements of the candidate ligands in response to the protein’s active site 
environment.  
3.2.16 Similarity Search  
The morphological similarity is a similarity technique dependent only on surface shape and 
charge characteristics of ligands (219). Morphological similarity is defined as a Gaussian 
function of the differences in the molecular surface distances of two molecules at weighted 
observation points on a uniform grid. The computed surface distances include both distances to 
the nearest atomic surface and distances to donor and acceptor surfaces. This function is 
dependent on the relative alignment of the molecules, and consequently their alignment and 
conformation must be optimized. The conformational optimization problem is solved by 
fragmentation, conformational search, alignment, and scoring, followed by incremental 
reconstruction from high-scoring aligned fragments. The alignment problem is addressed by 
exploiting the fact that two unaligned molecules or molecular fragments that have some degree 
of similarity will have some corresponding set of observers that are seeing the same things. 
Optimization of the similarity of two unaligned molecules or molecular fragments is enabled by 
finding similar sets of observers of each molecule that form triangles of the same size (219).  
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3.2.17 In silico ADME and toxicity screening  
Computational modeling tools were used to estimate the bioavailability, aqueous solubility, 
blood brain barrier potential, human intestinal absorption, the cytochrome P450 (i.e. CYP2D6) 
enzyme inhibition potential, mutagenicity, and hERG inhibition of the hits obtained from the 
database screening. The bioavailability, aqueous solubility, and human intestinal absorption were 
estimated using the Advanced Chemistry Development, Inc. (ACD/Labs)/ADME Boxes 
software while mutagenicity, hERG and CYP2D6 inhibition were estimated with ACD/Tox 
screening (ACD Labs, Toronto, Canada) (220). 
3.2.18 Statistical analysis   
All values were presented as mean+/-S.E.M. Microsoft Excel and Graphpad Prism 6 were used 
for statistical analysis. Two-tailed Student’s t-test was performed to determine differences 
between two groups. When comparing difference in more than two groups, one-way ANOVA 
(Dunnett test) was conducted. A value of p <0.05 was considered as statistically significant, 
shown as *p <0.05, **p <0.01, and ***p < 0.001. 
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3.3 RESULTS 
3.3.1 Generation of a structure-based pharmocophore model using a computational 
approach based on the conserved interactions between IKKα/β and NEMO   
Recognition of small molecules by proteins is largely mediated by molecular surface 
complementarities (221, 222). Our working hypothesis was that the protein-protein interaction 
site of NEMO/IKKβ protein complex is a potentially good target for in-silico drug development. 
To test this hypothesis, we generated a structure-based pharmacophore model. The X-ray 
structure of the NEMO/IKKβ complex retrieved from the Protein Data Bank [PDB ID: 3BRV] 
(42), was used to generate a structure-based pharmacophore (Fig. 13A) to investigate the 
chemical features important in the protein-protein interaction. This was performed using the 
pharmacophore generation module of LigandScout (217, 218).  
Each interacting atom from each residue was “translated” into a pharmacophoric feature, 
resulting in the structure-based pharmacophore (Fig. 13B). The structure-based pharmacophore 
model consists of eight features (F1,…, F8) and 13 exclusion volumes (V1, …, V13) 
representing important atoms from the protein’s environment. 
This model was used to screen a subset of the drug-like ZINC 10.0 database set 
(approximately 3.5 million compounds) (219). We were able to identify 161 hits that matched at 
least 6 features out of eight (F1, …, F8) of the pharmacophore model. Twenty hits had an RMSD 
< 1, and were further prioritized using Absorption, Distribution, Metabolism, Excretion, and 
Toxicity (ADME/Tox) predicted properties. Three compounds have successfully passed these 





Figure 13: The development of a structure-based pharmacophore model for in silico screen 
of NBD mimetics. (A) Interacting residues extracted from the X-ray structure of the 
NEMO/IKKβ complex [PDB ID: 3BRV] used in the generation of the structure-based 
pharmacophore model (42). (B) A three-dimensional representation of the structure-based 
pharmacophore model. Three hydrophobic groups (F2, F4 and F7 - yellow spheres), one 
hydrogen-bond acceptor features (F3 - red sphere), one hydrogen-bond donor (F5 - green 
sphere), one positive ionizable area (F8 – blue sphere), one negative ionizable (F6 – red sphere) 
and 13 excluded volumes (gray spheres) are shown. (C) Chemical structures of three compounds 
that entered biological testing (219).  
3.3.2 Identification of small molecule inhibitors of NF-κB activation. 
To test if the small molecules identified by the in silico screen inhibit NF-κB activation, a 
HEK293 cell line stably expressing a luciferase reporter driven by a synthetic, NF-κB-dependent 
promoter was utilized. To induce NF-κB activation, cells were treated with 10 ng/ml of TNF-α 
and harvested three hours post-treatment for analysis of luciferase activity. Treatment with 
ZINC12909780 slightly downregulated NF-κB activation at a concentration of 100 μM whereas 
the luciferase activity remained unchanged in cells treated with ZINC05682974 or 
ZINC09327678 (Fig. 14A). To determine if ZINC12909780 inhibited NF-κB in a dose 
dependent manner, concentrations were tested at 0, 6.25, 25, 50 and 100 μM. We found that only 
high concentrations (50 and 100 μM) of the compound were able to inhibit TNF-α-induced NF-
κB activation significantly, which is consistent with previous studies that NBD peptide tends to 
work at higher concentrations compared to kinase inhibitors in cell culture (Fig. 14B).  
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To identify NBD mimetics with higher biological activity than ZINC12909780 or the 
NBD peptide, we next screened the ZINC 10.0 database (approximately 3.5 million compounds) 
in silico for structurally similar compounds (223). Fifteen analogs with a similarity score > 90% 
were identified, and thirteen that passed all the ADME/Tox filters were acquired for testing 
(Table 1). Four of the compounds, ZINC9642366 (Zinc1), ZINC3369392 (Zinc5), ZINC3269261 
(Zinc8) and ZINC3264658 (Zinc9), lowered NF-κΒ activity robustly while other analogs had 
minimal effects (Fig. 14C). To rule out the possibility that the reduction observed in luciferase 
assays was actually caused by drug toxicity, an MTT assay was performed to assess cell 
viability. Treatment with ZINC8 resulted in 40% of cell death at 24 hours, suggesting that at 
least part of the reduction in luciferase activity could be attributed to cytotoxicity (Fig. 14D). 
Since ZINC5 displayed potent NF-κB inhibitory efficacy in cell culture showing little toxicity 
(less than 10%), it was tested for dose-response inhibition of NF-B. ZINC5 showed a greater 
extent of inhibitory effect compared to ZINC12909780 at 50 and 100 μM, with no cell toxicity 
observed, suggesting a higher efficacy of ZINC5 (Fig. 14E & F).  
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Figure 14: Identification of small molecules that suppress TNF-α-induced NF-κB 
activation. (A) HEK 293 cells stably expressing NF-κB luciferase reporter were pretreated with 
indicated small molecules at 100 μM for 30 min, followed by stimulation with TNF-α (10 ng/ml) 
for 3 hours. Luciferase activity was normalized to untreated stimulated control cells. Data show 
the mean values of two independent experiments +/- SD. (B) A dose-dependent response of 
ZINC12909780 was tested by NF-κΒ luciferase assay in HEK293 cells. Three independent 
experiments were performed and data shown represent mean +/- SD. (C) NF-κB luciferase assay 
was performed at 100 μM to screen for small molecules with greater NF-κB inhibitory effect. 
Data show the pooled results of five independent experiments and are the mean +/- SD.  (D) The 
same HEK293 cells were cultured in the presence of 100 μM of indicated derivatives for 24 hr 
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and cell survival was determined by MTT assay. Cell viability was calculated by normalizing to 
untreated cells. (E) Dose-dependent inhibitory effects and (D) drug toxicity were determined for 
ZINC5 at 0, 25, 50 and 100 μM. HEK293 were cultivated in the presence of ZINC5 at listed 
concentrations for 24 hr and drug toxicity was assessed by MTT assay. Data represent the mean 




















Table 1: Small molecule derivatives selected from ZINC 10.0 database share structural 
similarity to ZINC12909780. 
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3.3.3 NBD mimetics inhibit NF-κB DNA binding activity. 
To confirm that the NBD mimetics reduce IKK activity, the extent of phosphorylation of the 
IKK target, IκBα, in response to 10 ng/ml of TNF-α was determined by Western blot at 0, 5 and 
10 min after TNF-α stimulation. ZINC5 reduced the level of p-IκBα dramatically following 
stimulation, while ZINC12909780 led to a mild reduction (Fig. 15A). To determine if the 
mimetics also reduce NF-κΒ DNA binding activity, electrophoretic mobility shift assay (EMSA) 
was conducted both in vitro and in vivo. ZINC5 and ZINC12909780 significantly decreased 
TNFα-induced NF-κB DNA binding activity at 200 μM in C2C12 cells, a mouse myoblast cell 
line (Fig. 15B). Similarly, a single ip injection of these two small molecules at 10 mg/kg 
inhibited NF-κB DNA binding activity in quadriceps in mdx mice (Fig. 15C). However, chronic 







Figure 15: Two identified small molecules reduce NF-κB DNA binding activity in vivo and 
in vitro. (A) Levels of p-IκBα with or without treatment in response to TNF-α were determined 
by western blot analysis. HEK293 cells were pretreated with DMSO, ZINC12909780 and ZINC5 
at 100 μM for 30 mins followed by the stimulation of 10 ng/ml of TNF-α for 0, 5 and 10 min. 
Cell lysates were prepared for immunoblot against p-IκBα. GAPDH was used as a loading 
control. (B) EMSA analysis detecting NF-κB DNA binding activity was performed in C2C12 
myoblasts. Cells were pretreated with 200 μM of DMSO, ZINC12909780 and ZINC5 in serum-
free media for 1 hr. TNF-α was then added directly to the media to a final concentration of 10 
ng/ml and incubated for 15 min. Nuclear extract was obtained for EMSA analysis. (C) EMSA 
analysis assessing NF-κB DNA binding activity was performed in quadriceps from mdx mice 
post-treatment. Single dose of ZINC12909780 and ZINC5 at 10 mg/kg was given by i.p. to mdx 
mice. Quadriceps was harvested at 1 hr and 2 hrs post-injection for EMSA analysis.  
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3.3.4 Optimization of the NBD mimetics  
ZINC5 and ZINC12909780 both contain ester bonds, leading to their rapid degradation in the 
presence of serum (data not shown). Thus seven rounds of structural modification and 
optimization were performed to improve bioactivity and stability and more than one hundred 
small molecules were tested (data not shown). Four lead NBD mimetics were identified that 
showed enhanced inhibitory effects, compared to the original ZINC compounds, including three 
non-esters, SR12343, SR12460 and SR12454, and one ester SR11481 (Fig. 17A & B). To 
minimize the influence of drug toxicity on the screening assay, a renilla luciferase reporter 
driven by the SV40 promoter was cotransfected with the NF-κB luciferase reporter into HEK293 
cells as a co-reporter for normalization. Three non-esters showed markedly enhanced inhibition 
of TNF-α-mediated NF-κB activation: SR12460 with an IC50 of 11.34 μM, SR12454 of 20.24 
μM and SR12343 of 37.02 μM (Table 2 & Fig. 17B & Fig. 16A). The ester SR11481 only 
worked at a higher concentration, with an IC50 of 45.03 μM, possibly due to the instability of the 
ester bond (Fig. 17B). To determine whether these more potent, novel NBD mimetics disrupt 
NEMO and IKKβ binding, co-immunoprecipitation was performed using Raw 264.7 
macrophages (Fig. 17C) and HEK293 cells (data not shown). After treatment with the mimetics 
or NBD peptide, NEMO was immunoprecipitated by an anti-NEMO antibody and IKKβ was 
immunoblotted to determine the binding of IKKβ to NEMO. The control 8K-NBD peptide was 
able to disrupt the protein-protein interaction in macrophages at 400 μM (Fig. 17C). All four of 
the mimetics dissociated IKKβ-NEMO interaction at 100 μM, with SR12343, having the 
strongest activity (Fig. 17C).  
To determine whether the inhibitory effect of the mimetics is TNF-α-dependent, LPS-
mediated NF-κB activation via TLR4 was examined to determine a broader inhibitory effect of 
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the novel NBD mimetics. NF-κB was stimulated in Raw 264.7 by 1 ug/ml of LPS for 2hr and 
genes transcriptionally regulated by NF-κB were determined by qRT-PCR analysis. Both an IKK 
active site inhibitor IKKi VII (2 μM) and the 8K-NBD peptide (400 μM) were included as 
positive controls and the expression of COX2, IL-6, IL-1β, TNF-α, IκBα and iNOS were 
assessed. SR12460 and SR12454, which are closely structure-related, were able to significantly 
downregulate the transcription of all NF-κB target genes tested, indicating a comprehensive 
inhibition of LPS-induced NF-κB activation (Fig. 17D). SR12343 displayed a similar profile to 
8K-NBD peptide, showing significant inhibition on COX2, IL-6 and iNOS expression at a much 
lower concentration (50 μM) compared to NBD peptide (400 μM). SR11481 failed to suppress 
all NF-κB target genes, likely due to its poor stability. Interestingly, IKKi VII, while able to 
inhibit most NF-κB target gene expression, failed to downregulate iNOS expression, which was 
significantly inhibited by the NBD peptide and all non-ester NBD mimetics. This suggests that 
IKK inhibitors targeting the ATP-binding pocket, likely downregulates the expression of a 
distinct subset of genes.  
To confirm the qRT-PCR result, LPS-mediated IL-6 production was analyzed in Raw 
264.7 cells by ELISA. SR12460 and SR12454 were able to decrease mIL-6 production in a dose-
dependent manner, decreasing by half at 25 μM and even to a greater extent at 50 μM (Fig. 17E). 
Similarly, SR12343 suppressed mIL-6 production in a dose-dependent manner. However, 
SR12343 exhibited a less potent inhibitory effect and required a higher working concentration, 
which is consistent with the IC50 in HEK293 cells. Although SR11481 failed to downregulate IL-
6 significantly at the mRNA level, there was reduction in the accumulation of IL-6 protein at 24 
hr. Moreover, SR11481 appears to work more efficiently at a lower concentration around 25 μM. 
Taken together, four lead compounds were identified through seven rounds of optimization and 
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modification. They exhibited suppression on both TNF-α- and LPS-induced NF-κΒ activation by 
blocking NEMO and IKKβ association at a significantly lower concentration than NBD peptide. 
          Table 2: The IC50 of NBD Mimetics. 









Figure 16: Dose-dependent curve of lead NBD mimetics. (A) Dose-dependent curve of NBD 





Figure 17: Modified lead NBD mimetics inhibit TNF-α- and LPS-induced NF-κB activation 
by disrupting the association between NEMO and IKKβ. (A) Structures of  top NBD 
mimetics after seven rounds of optimization and screen. (B) Measurement of NF-κB activation in 
response to TNF-α by a luciferase assay. HEK293 cells cotransfected with NF-κB luciferase 
reporter and SV40-Renilla plasmids were pretreated with DMSO or listed small molecules at 0, 
25, 50, 100 and 150 μM for 30 min, followed by the induction of TNF-α for 3hr. Dual-luciferase 
reporter assay was then performed to detect NF-κB luciferase and Renilla luciferase activity 
sequentially. The relative luciferase activity was calculated by normalizing NF-κB luciferase to 
Renilla luciferase activity. Data shown are representative of 2-3 independent experiments. (C) 
Co-immunoprecipitation (Co-IP) analysis detecting protein-protein interaction between IKKβ 
and NEMO. Raw 264.7 cells were pretreated with indicated drugs, DMSO, 8K-NBD peptide 
(400 μM), and 100 μM of SR12460, SR12343, SR12454 and SR11481 for 30 min. Cells were 
then harvested for CO-IP. NEMO was immunoprecipitated from the cell lysate by using an anti-
NEMO antibody and the binding product was then subjected to immunoblot probing for IKKβ. 
ΝΕΜΟ was probed as a loading control. (D) NBD mimetics downregulated the expression of 
NF-κB target genes in reponse to LPS. Raw 264.7 cells were pretreated with indicated drugs for 
30 min and then stimulated with 1 ug/ml of LPS for 2 hrs. Cells were then harvested for RNA 
extraction and qRT-PCR analysis. Relative expression of target genes was normalized to β-actin. 
Drug concentrations used are as follows: IKKi VII (2 μM), 8K-NBD peptide (200 μM), SR 
12343 (50 μM), SR12460 (50 μM), SR12454 (50 μM) and SR11481 (50 μM). Data are 
representative of 2 independent experiments. (E) Mouse IL-6 production induced by LPS was 
downregulated by NBD mimetics. Raw 264.7 cells pretreated with DMSO or drugs at indicated 
 83 
concentrations were exposed to 1 ug/ml of LPS for 24 hr and supernatant was collected for 
ELISA analysis of mouse IL-6.  
3.3.5 Novel NBD Mimetics suppress LPS-induced acute pulmonary inflammation in vivo   
To determine the stability of the NBD mimetics in vivo, the pharmacokinetics of the compounds 
was determined in serum following ip injection. SR12460 showed significant stability 2 hr after 
injection. SR12343 and SR12454 showed moderate stability, whereas SR11481 was extremely 
unstable with undetectable levels at 2 hr (Fig. 18A). Since SR12454 and SR12460 share very 
similar chemical structures and SR11481 is extremely unstable in vivo, SR12460 and SR12343 
were selected for further in vivo analysis.  
SR12343 and SR12460 initially were tested in an acute model of LPS-induced systemic 
endotoxemia to determine their NF-κB inhibitory effects in vivo. C57BL/6J mice were pretreated 
with vehicle control, 8K-NBD peptide or NBD mimetics at 10 mg/kg for 30 min, followed by 
LPS induction at 10 mg/kg (Fig. 18B). Lung and liver were harvested 2-4 hr post-treatment for 
qRT-PCR analysis of NF-κB target genes. SR12343 was able to downregulate NF-κB 
transcriptional activity significantly in lung, as demonstrated by the inhibition of iNOS, iκΒα, 
COX2 and IL-6, while leaving TNF-α unchanged (Fig. 18C). Its NF-κΒ inhibitory effect in liver 
was less effective compared to lung, inhibiting only COX2 expression significantly (Fig. 18C). 
Intriguingly, although SR12460 is more stable than SR12343, its inhibition of NF-κB/IKK in 
liver and lung were less potent compared to SR12343 (Fig. 18C). Taken together, the results 
demonstrate that SR12343 and SR12460 are effective at attenuating LPS-induced acute lung 
inflammation by suppressing NF-κB target gene expression.  
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Figure 18: Newly identified NBD mimetics suppress LPS-induced acute inflammation in 
vivo. (A) The bioavailability property of SR12460, SR12343, SR12454 and SR11481. 
Concentrations of NBD mimetics were determined in plasma, brain, muscle, spleen and liver 2 
hrs post a single i.p. injection of 10 mg/kg of drugs. n=3 per group. n.d. means non-detectable.  
(B) Shown are the model of LPS-induced acute inflammation and the treatment regimen. (C) 
NBD Mimetics suppressed LPS-induced acute inflammation in lung and liver by downregulating 
NF-κB target gene expression. Acute inflammation was induced by intraperitoneal injection of 
10 mg/kg LPS. Vehicle, SR12343, SR12460 and 8K-NBD peptide were dosed at 10mg/kg 30 
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min prior to the LPS treatment. Lung and liver were collected 2-4 hr post-LPS injection and 
analyzed by qRT-PCR. n=3-8 each group. 
3.3.6 Novel NBD Mimetics improve muscle pathology in mdx mice  
Since SR12343 and SR12460 both reduced LPS-induced NF-κB activation in vivo, they were 
further tested in mdx mice, a mouse model of Duchenne muscular dystrophy. Mdx mice develop 
normally at birth, and then undergo a massive myonecrosis starting at three weeks. Treatment of 
mdx mice with IKK/NF-kB inhibitors effectively reduces inflammation, block necrosis and 
increase muscle regeneration. Mdx mice were chronically treated with vehicle, SR12343, 
SR12460 or 8K-NBD starting from day 21, 3 times/week for 4 weeks (Fig. 19A). No significant 
weight loss was observed in chronically treated mdx mice (Fig. 20A). To determine if SR12343 
and SR12460 improve muscle pathology, tibialis anterior (TA) muscle was stained with 
hematoxylin and eosin (H&E) to assess inflammatory infiltration, necrosis, central nucleation 
and fibrosis. Vehicle treated TA muscles exhibited extensive infiltration and necrosis as reflected 
by clusters of inflammatory cells, disorganized myofibers and nonuniform staining, with limited 
muscle regeneration. Consistent with previous studies, 8K-NBD peptide reduced inflammatory 
cell infiltration and necrosis and also promoted muscle regeneration as shown by centralized 
nuclei (224, 225). Interestingly, SR12343 treatment led to the most significant pathological 
improvement, as represented by limited infiltration and enhanced muscle reconstruction (Fig. 
19B&C). Similarly, SR12460 treatment partly improved muscle pathology, although not as 
significant as SR12343. As compared to the control group, qRT-PCR analysis revealed 
significant improvement of myofiber regeneration in SR12343 treated TA muscle, by increasing 
expression of eMyHC as well as Pax 7, a marker of skeletal muscle satellite cells (Fig. 19D). 
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SR12460 and 8K-NBD also increased eMyHC expression, but to a lower extent compared to 
SR12343. Fiber size in centrally nucleated myofibers and total myofibers were also smaller in 
mice treated with SR12343 and 8K-NBD, indicating active reconstruction of myofiber during the 
regenerative phase (Fig. 19E).  
To determine muscle strength post-treatment, grip strength test on forelimbs was 
performed 2 weeks and 4 weeks post-treatment. Compared to vehicle group, SR12343 
significantly improved forelimb strength after 2 weeks of treatment, indicating rapid muscle 
repair and inflammatory flameout. All treatment groups, compared to control, significantly 
strengthened forelimb muscles 4 weeks post-treatment (Fig. 19F). Taken together, the two lead 
compounds, SR12460 and, in particular, SR12343, markedly improved muscle function and 




Figure 19: NBD mimetics improve muscular pathology and grip strength in mdx mice. (A) 
Shown is the treatment regimen of NBD mimetics in mdx mice. (B) H&E staining of tibialis 
anterior muscle from 7-week-old age-matched mdx mice, treated or untreated. Images were taken 
at the magnification of 10x. Representative images were shown for each treatment group. (C) 
Quantitation of the percentage of area exhibiting necrosis or infiltration. (D) qRT-PCR analysis 
of eMyHC and Pax 7 in tibialis anterior muscle. (E) Quantitation of minimum Feret’s diameter in 
centrally nucleated and total myofibers. Myocytes were outlined with laminin staining and were 
quantified by using Image J. (F) Forelimb force was determined by grip strength test. 5-wk-old 
(2 weeks post treatment) and 7-wk-old (4 weeks post treatment) mdx mice, treated with vehicle, 
NBD peptide or NBD Mimetics, were tested for forelimb grip strength. Five sequential tests 
were performed and the force was normalized to body weight. Data were shown as mean +/- 
SEM. Dosages used are as follows: SR 12343 (30 mg/kg), SR 12460(30 mg/kg) and 8K-NBD 





Figure 20: NBD mimetics display no effects on body weight in treated mdx mice. (A) Body 
weight was monitored in chronically treated mdx mice and no significant differences were found. 
3.4 DISCUSSION 
Since a peptide derived from the NEMO binding domain in IKKβ has been demonstrated to be 
highly therapeutic in numerous mouse models of inflammatory and degenerative diseases, the 
development of NBD mimetics would have significant clinical utility.  Here we identified and 
optimized novel NBD mimetics that selectively inhibited IKK/NF-κB activity. The two lead 
compounds, SR12343 and SR12460, inhibited both TNF-α- and LPS-induced NF-κB activation 
more effectively and at a lower concentration than the NBD peptide in both HEK293 and Raw 
264.7 cells. The NBD mimetics also were demonstrated to disrupt the IKK complexes by co-
immunoprecipitation, which is distinct from the existing ATP-competitive inhibitors targeting 
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IKKβ or IKKα. Although SR12343 is less stable in vivo compared to SR12460, it showed 
stonger inhibitory and therapeutic effects in the LPS-induced ALI model and mdx mice, where 
the pathology is mainly mediated by immune cells.  
To identify the NBD mimetics, a computational screening based on the pharmacophore 
model was used (42).  A crystal structure study previously identified amino acid residues W741, 
W739 and F734 as the essential hydrophobic motifs interacting with NEMO (42). Also, a 
mutated 11-mer NBD peptide (735-745), with substitutions of alanine for W741 and W739, lost 
NEMO binding ability (43). Moreover, a longer IKKβ-derived peptide (701-746) containing all 
residues and domains, were tested and shown to exhibit the strongest affinity to NEMO with IC50 
around 10 nm, while the traditional NBD peptide (11-mer) was less potent, with IC50 around 100 
μm (42, 226). Thus, to identify NBD mimetics, the third residue F734 (in the linker domain) that 
was left out of the 11-mer NBD peptide, was included in our pharmacophore model and in silico 
screening. The NBD mimetics were able to inhibit NF-kB activity in a dose-dependent manner 
with an EC50 around 10-40 μM, which is still lower than the extent of inhibition with the 45-mer 
NBD peptide (42, 226). These results are consistent with the current evidence that the IKK helix 
region significantly contributes to the high binding affinity between IKKβ and NEMO (227).  
We demonstrated that the novel NBD mimetics were able to block preformed 
NEMO/IKKβ complexes, consistent with previous reports that NBD peptide blocks the 
association in preformed IKK complexes (43, 226). However, there is evidence suggesting that 
NBD peptide preferably forces IKKβ, but not IKKα, to leave the IKK complex (226). It also has 
been reported that NBD peptide disrupts the association between IKKα and NEMO and block 
IL-1 induced IKKβ-independent NF-κB activation via IKKα at a much lower affinity (43, 44). 
This could explain why NBD peptide exhibited greater therapeutic efficacy in various in vivo 
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models than IKK kinase inhitors, most of which preferentially target IKKβ. Clearly, further 
analysis of the interaction of not only the mimetics with IKK, but also the NBD peptide is 
needed.   
The NBD peptide was reported not to affect basal activity of NF-κB (11, 226). We too 
have not observed a signficant reduction in basal NF-κB transcription. This is important since 
complete abolishment of NF-κB activity in mice lacking IKKβ has been demonstrated to lead to 
extensive apoptosis, tissue injury and embryonic lethality, due to TNFα-induced apoptosis (13, 
228). We observed no apparent signs of liver or kidney toxicity, nor infection tendency from the 
chronic treatment study, consistent with previous findings that no signs of toxicity has been 
reported with chronic dosing of NBD peptide (211).  
It is of interest that the NBD mimetics inhibited a unique subset of target genes compared 
to IKK kinase inhibitors, particularly iNOS which is involved in the production of nitric oxide. 
The role of iNOS, as a central mediator of neutrophil recruitment, has been well established in 
the pathophysiology of LPS-induced ALI and sepsis (229, 230). iNOS-knockout mice and mice 
treated with NOS inhibitors have been reported to exhibit an attenuated inflammatory response 
and tissue injury in multiple models of lung inflammation (231-234). Thus, NBD mimetics may 
exhibit stronger therapeutic effects in inflammatory diseases driven by iNOS production. 
The analysis of the NBD mimetics in mdx mice provides compelling evidence that the 
small molecule NBD mimetics inhibited pro-inflammatory responses and improved muscle 
degeneration, showing an even greater improvement in pathology than NBD peptide. IKK is 
responsible for persistently amplified NF-κB signaling cascade and the exhaustion of 
regeneration capacity of injured myofibers, contributing to the pathology and phenotype of 
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muscle dystrophy in DMD (48). Thus, novel NBD mimetics could be used clinically to treat 
DMD. 
We previously have demonstrated that chronic treatment of the Ercc1-/∆ mouse model of 
accelerated aging with the NBD peptide delayed onset of numerous age-related symptoms, 
improved pathology and reduced cellular senescence.  Similar to the NBD peptide, chronic 
treatment of Ercc1-/∆ mice with SR12343 resulted in an extension of healthspan.  In addition, in a 
moue model of skin photoaging, topical treatment with SR12343 improved molecular markers of 
skin aging as well as the overall appearance of the skin.  Thus these novel NBD mimetics could 
be used not only for treatment of inflammatory and degenerative diseases, but also aging.     
Collectively, our data demonstrate that the novel small molecule NBD mimetics are 
potent and highly selective IKK inhibitors by disrupting the association of IKK complexes. They 
exhibited significant inhibitory effects on NF-κB activation in the model of LPS-induced ALI 
and murine model of DMD (mdx mice), suggesting the potential of NBD mimetics becoming a 
distinct class of anti-inflammatory drugs. Taken together, NBD mimetics may provide 
therapeutic values for the chronic management of inflammatory diseases and cancers in the 
future. 
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4.0  A NOVEL NBD MIMETIC EXTENDS HEALTHSPAN AND IMPROVES 
METABOLIC ABNORMALITIES IN Ercc1-/Δ MICE 
4.1 INTRODUCTION 
Aging, referring to a state of gradual deterioration of physical activity and organ function, has 
been associated with various aging-related diseases, including diabetes, atherosclerosis, 
intervertebral disc degeneration, osteoporosis, neurodegeneration and cancer (201). The concept 
of cellular senescence was first described as irreversible growth arrest, termed replicative 
senescence (85). Extensive studies have shown that DNA damage, telomere shortening, 
oncogene activation and oxidative stress all contribute to cellular senescence (87, 96). Recently, 
Baker et al. demonstrated that the clearance of p16Ink4a-positive senescent cells reduced tissue 
senescence and moreover extended healthspan in the BubR1H/H mouse model of accelerated 
aging (122). 
Cellular senescence is a mechanism that cells employ in response to endogenous and 
exogenous stresses. Two major effector pathways p53/p21 and p16/Rb have been demonstrated 
to increase with aging (87). DNA damage induced by telomere shortening, genotoxic stress and 
oxidative stress induces a signaling cascade to maintain the genome integrity, called the DNA 
damage response (DDR) (87, 96). DDR signaling has been demonstrated to mediate cell growth 
arrest by suppressing Cdk2 via p53/p21 (87). Similarly, the p16/Rb pathway inhibits Cdk4/Cdk6 
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to block cell cycle progression, which is a common pathway employed by oncogene-induced 
senescence (OIS) that is DDR-independent (87, 235). Senescent cells exhibit a senescence-
associated secretory phenotype (SASP), producing cytokines, chemokines, growth factors and 
extracellular proteases, which negatively impact neighboring cells (129, 132). In particular, pro-
inflammatory cytokines, interleukin-6 (IL-6), interleukin-1α (IL-1α) and tumor necrosis factor-α 
(TNF-α), were shown to enhance primary senescence and induce secondary senescence in cell-
autonomous and cell-nonautonomous pathways in vitro (129, 165, 166). 
A causal role of NF-κB activation in natural and accelerated aging was recently 
established. Genetic (p65+/-) and pharmacologic (NBD peptide) inhibition of NF-κB delayed the 
onset of aging symptoms and extended healthspan in Ercc1-/Δ progeroid mice (137). 
Hypothalamus- and brain-specific knockout of IKKβ attenuated aging-related neurodegeneration 
and extended lifespan, suggesting a causal role of IKKβ/NF-κB in aging, as well as the 
involvement of hypothalamus in systemic aging (139). The transcriptional activity of RelA/p65 
can be negatively regulated by p50 homodimers (3). Thus, in contrast, Nfkb1-/- (p50-/-) mice, 
where RelA/p65 is chronically activated, exhibited reduced lifespan, impaired tissue regeneration 
and neurodegeneration (141, 143, 173, 174).  
NBD peptide contains eleven amino acids derived from the NEMO-binding domain 
(NBD) of the C-terminus of IKKβ/α and is a highly selective IKK complex inhibitor, by 
disrupting the association between IKKβ/α and NEMO (11). The therapeutic effects of NBD 
peptide have been well established in various murine disease models driven by NF-κB activation, 
including chronic colitis, Duchenne muscular dystrophy (DMD), Parkinson’s disease, Type 1 
diabetes, osteoclastogenesis and diffuse large B-cell lymphoma (46, 47, 49, 51, 212, 224, 225). A 
small molecule inhibitor, SR12343, which was developed based on NBD peptide, has been 
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shown to work similarly to the peptide (Chapter 3) by showing positive therapeutic effects in a 
murine model of DMD. 
In this study, we used the Ercc1-/Δ mouse model of accelerated aging, which 
spontaneously develops osteoporosis, sarcopenia, disc degeneration, glomerulonephropathy and 
neurodegeneration, to study DNA damage-induced cellular senescence and aging. Here we 
further examined the role of NF-κB in senescence and aging using the small molecule inhibitor 
SR12343. Chronic administration of SR12343 extended healthspan in Ercc1-/∆ mice as well as 
reduced the level of cellular senescence in tissues. Moreover, SR12343 was shown to attenuate 
aging-related lipodystrophy and impaired glucose tolerance partly by reducing senescence in the 
adipose tissue. Thus, our results suggest SR12343 could be a promising clinical approach to 
attenuate frailty and aging-related diseases. 
4.2 MATERIALS AND METHODS 
4.2.1 Cells and mice  
Primary mouse embryonic fibroblasts (MEFs) were isolated on embryonic day 12.5-13.5. In 
brief, mouse embryos were isolated from yolk sac followed by the complete removal of viscera, 
lung and heart if presented. Embryos were then minced into fine chunks, fed with MEFs 
medium, cultivated under 3% oxygen to reduce stresses. Cells were split at 1:3 when reaching 
confluence. MEFs were grown at a 1:1 ratio of Dulbecco’s Modification of Eagles Medium 
(supplemented with 4.5g/L glucose and L-glutamine) and Ham’s F10 medium, supplemented 
with 10% fetal bovine serum, penicillin, streptomycin and non-essential amino acid. To induce 
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oxidative stress-mediated DNA damage, Ercc1-/- MEFs were switched to 20% oxygen for 
cultivation starting at passage 3. 
Ercc1+/- and Ercc1+/Δ mice from C57BL/6J and FVB/n backgrounds were crossed to 
generate Ercc1-/Δ mice to prevent potential strain-specific pathology. For low dose study, 6-
week-old sex-matched Ercc1-/Δ mice were dosed with 10 mg/kg of SR12343 or vehicle by 
intraperitoneal injection three times per week up untill 15 weeks of age. For high dose study, 8-
week-old sex-matched Ercc1-/Δ mice were dosed with 30 mg/kg of SR12343 or vehicle by 
intraperitoneal injection 3 times per week untill 15 weeks of age. SR12343 was formulated in 
10:10:80 of DMSO:Tween 80:water for in vivo administration. Animal protocols used in this 
study were approved by Scripps Florida Institutional Animal Care and Use Committees. 
4.2.2 Health Evaluation  
Health assessment was conducted twice per week to evaluate age-related symptoms, including 
body weight, tremor, forelimb grip strength, kyphosis, hindlimb paralysis, gait disorder, dystonia 
and ataxia. Kyphosis, body condition and coat condition were used to reflect general health 
conditions. Ataxia, dystonia, gait disorder and tremor were used as indicators of aging-related 
neurodegeneration. Muscle wasting was studies by monitoring hindlimb paralysis and forelimb 
grip strength. All aging symptoms were scored based on a scale of 0, 0.5 and 1, with the 
exception of dystonia that has a scale from 0 to 5. The sum of aging scores of each group was 
used to determine the overall aging conditions, with zero means no symptom presented. 
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4.2.3 Nuclear magnetic resonance (NMR) 
Bruker’s minispec LF50 body composition analyzer was used to measure lean tissue, fat and 
fluid in mice according to the manufacturer’s instructions. Mice were placed into a restrainer and 
body composition was measured by the analyzer. Readings of lean tissue, fat and fluid were 
normalized to body weight to get the percentage of each body composition.  
4.2.4 Oral glucose tolerance test (OGTT)  
11-week-old mice were fasted overnight prior to OGTT test. Baseline fasting blood glucose was 
obtained before glucose administration at 0 min. A bolus of glucose (2g/kg) was administrated to 
each mouse by oral gavage and blood glucose was measured at 5, 15, 30, 60 min with tail-tip 
blood. 
4.2.5 Senescence-associated β-galactosidase staining in vivo and in vitro  
Fresh fat was fixed in 2% formaldehyde and 0.2% glutaraldehyde in PBS for 10 minutes at room 
temperature. After the removal of fixative, adipose tissue was stained with SA-βgal staining (pH 
6.0) solution (40 mM citric acid in sodium phosphate buffer, 5 mM K4[Fe(CN)6] 3H2O, 5 mM 
K3[Fe(CN)6], 150 mM sodium chloride, 2 mM magnesium chloride and 1 mg/ml X-gal dissolved 
in N,N-dimethylformamide) for 16-20 hours in a 37oC incubator without CO2 injection. Images 
were taken at 5 hr into the staining. Fresh liver tissue was fixed in 10% neutral buffered formalin 
(NBF) for 3-4 hours and then transfered to 30% sucrose overnight. Tissue was then imbeded in 
optimal cutting temperature compound (OCT) and stored at -80oC. 5μM cyrosetions were 
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performed and slides were stained in SA-βgal staining solution (pH 5.8) at 37oC for 16-24 hours. 
To quantify, 10 random images were captured using a bright-field microscopy at 10x 
magnification and the number of SA-βgal+ cells per field was counted. The quantification was 
shown as mean+/- SE.  
4.2.6 Fluorescence-based C12FDG staining 
Ercc1-/- MEFs grown in 20% oxygen were seeded into 96-well plates, allowed to attach 
overnight and treated with vehicle or SR12343 at indicated concentration for 48 hr. Prior to 
staining, cells were incubated with 100 nM of bafilomycin A1 for 1 hr to induce lysosomal 
alkalinization. C12FDG was then added to the media to reach a final concentration of 10 μM and 
incubated for 2 hr. Images were captured and analyzed by IN Cell Analyzer 6000 (GE 
healthcare). Percentage of positive cells was calculated by dividing senescent cells (C12FDG) by 
total cell number (DAPI). 
4.2.7 Quantitative reverse transcription-polymerase chain reaction   
Snap frozen tissues were preserved in RNAlater RNA stabilization solution (ThermoFisher). 
Total RNA was extracted using TRIZOL reagent  (Life Technologies) and 1.5 ug of RNA was 
transcribed into complementary DNA (cDNA) using SuperScript VILO cDNA synthesis kit. 
qRT-PCR was performed in a StepOnePlus Real-Time PCR system using Platinum SYBR Green 
qPCR SuperMix-UDG (ThermoFisher). Target gene expression was calculated using the 
comparative CT method (ΔΔCT) and normalized to an internal control gene Actb (β-actin). 
Primers used are as follows: Cdkn1a (p21) forward: GTCAGGCTGGTCTGCCTCCG; Cdkn1a 
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(p21) reverse: CGGTCCCGTGGACAGTGAGCAG; Cdkn2a (p16) forward: 
CCCAACGCCCCGAACT; Cdkn2a (p16) reverse: GCAGAAGAGCTGCTACGTGAA; Tnf  
(TNF) forward: CTATGTCTCAGCCTCTTCTC; Tnf  (TNF) reverse: 
CATTTGGGAACTTCTCATCC; Il6 (IL-6) forward: AAGAAATGATGGATGCTACC; Il6 (IL-
6) reverse: GAGTTTCTGTATCTCTCTGAAG; Actb (β-actin) forward: 
GATGTATGAAGGCTTTGGTC; Actb (β-actin) reverse: TGTGCACTTTTATTGGTCTC; 
4.2.8 Statistical analysis 
All values were presented as mean+/-S.E.M. Microsoft Excel and Graphpad Prism 6 were used 
for statistical analysis. Two-tailed Student’s t-test was performed to determine differences 
between two groups. To determine differences in more than two groups, one-way ANOVA 
(Dunnett test) was used. A value of p <0.05 was considered as statistically significant, shown as 
*p <0.05, **p <0.01, and ***p < 0.001. 
4.3 RESULTS 
4.3.1 SR12343 extends the healthspan of Ercc1-/Δ mice  
Naturally aged wild type (WT) mice develop aging-associated symptoms over time, including 
graying hair, alopecia, kyphosis, cachexia, lipodystrophy, muscle wasting and gait disorder 
(141). The premature aging symptoms observed in Ercc1-/Δ mice recapitulate most natural aging 
features with the exception of developing more severe neurodegeneration (152). We previously 
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reported that p65/RelA heterozygosity or treatment with IKK/NF-κB inhibitor (8K-NBD 
peptide) delayed the onset of aging-related symptoms and improved aging pathology in multiple 
tissues in Ercc1-/Δ mice (137). As mentioned in Chapter 3, we developed a novel NBD mimetic 
(SR12343) that selectively suppresses IKK/NF-κB signaling by disrupting the association 
between IKKβ and NEMO. To determine its anti-aging effects, Ercc1-/Δ mice were dosed with 
vehicle or SR12343 three times per week for 8 weeks, starting from 6-8 weeks of age. Health 
assessments were performed twice per week to evaluate aging symptoms (Fig. 21A). Tremor, 
kyphosis, dystonia, ataxia, gait disorder, hindlimb paralysis and forelimb grip strength were 
scored separately. The composite score of all aging symptoms reflects the overall health 
condition of Ercc1-/Δ mice. Mice treated with SR12343 showed reduced frailty and delayed 
progression of aging symptoms (Fig. 21B). A gender-matched comparison also showed delayed 
onset, reduced severity and slowed progression of aging symptoms (Fig. 21C). Among 
neurodegenerative symptoms, dystonia occurs as early as 8 weeks and worsens gradually with 
time. We found significantly attenuated dystonia in mice treated with SR12343 (Fig. 21D). 
Taken together, the data demonstrated that SR12343, by inhibiting IKK/NF-κB activity, 
extended healthspan and delayed the onset of aging symptoms in progeroid mice. 
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Figure 21: Chronic treatment with IKK inhibitor (SR12343) extends healthspan in Ercc1-/Δ 
mice. (A) Ercc1-/Δ mice were treated i.p. with SR12343 or vehicle 3 times per week, starting 
from 6-8 weeks of age. Mice were sacrificed around 15 weeeks of age and tissues were collected 
for analysis. n=4-5 mice each group. (B) The sum of symptom score of Ercc1-/Δ mice was 
presented, reflecting general health condition, neurodegeneration and muscle wasting. (C) Pair-
based plotting of aging symptoms. Higher stacking score indicates early onset and/or rapid 
progression of aging symptoms. (D) Dystonia was measured twice per week and scored based on 
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the severity and the time required for the pathological contraction. Representative images were 
shown in the upper panels. n=4-5 each group. 
4.3.2 Chronic treatment with SR12343 decreases cellular senescence in Ercc1-/Δ progeroid 
mice 
8K-NBD peptide was previously demonstrated to extend healthspan in Ercc1-/Δ progeroid mice, 
likely by reducing levels of cellular senescence, as demonstrated by reduced SA-βgal staining in 
liver (137). To determine if SR12343 reduces senescence, we first tested the drug in primary 
Ercc1-/- mouse embryonic fibroblasts (MEFs), which exhibited accelerated cellular senescence 
under atmospheric oxygen levels (20%). Using C12FDG (a fluorescence-based staining specific 
for β-galactosidase), senescent cells were shown to be reduced from 50% to 35% by SR12343 
(100 mM) without inducing significant cell death, suggesting non-senolytic effects of SR12343 
(Fig. 22A). To assess the effect of SR12343 on cellular senescence in vivo, staining of 
senescence-associated β-galactosidase (SA-βgal), a biomarker of cellular senescence, was 
performed in liver, with senescent cells developing a blue color. A significant reduction of the 
number of SA-βgal+ hepatocytes was found in SR12343 treated animals (Fig. 22B). qRT-PCR 
analysis of aging biomarkers in liver revealed a reduction of IL-6 and TNFα expression, although 
this was not statistically significant yet (Fig. 22C). No significant changes in p16 and p21 
expression were found; however a trend toward a reduction of p16 expression was found in 
female mice (Fig. 22C). Taken together, chronic suppresion of IKK/NF-κB led to reduced 
cellular senescence in liver. 
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Figure 22: Chronic treatment of SR12343 reduces cellular senescence in liver in Ercc1-/Δ 
mice. (A) C12FDG staining was performed to assess cellular senescence in primary Ercc1-/- 
MEFs cultured in 20% oxygen. Cells were seeded overnight to allow attachment and treated with 
vehicle (CTRL), IKKi VII (600 nm), rapamycin (200 nm) or SR12343 (100 μM) for 48 hour 
prior to reading. Senolytic effects were determined by DAPI counterstain. The absolute number 
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of live cells (DAPI) was counted by In Cell analyzer 6000 and was normalized to untreated 
controls to obtain the % of cell survival. (B) Treated or untreated livers from 15-week-old sex-
match Ercc1-/Δ mice were stained for SA-βgal. Ten random fields (at 10x magnification) were 
captured and data were presented as the average of the absolute number of SA-βgal+ cells. 
Representative images were taken at 20x magnification. n=3 mice each group. (C) qRT-PCR 
analysis of livers was performed to evaluate the expression of senescent markers and SASP 
factors. p16, p21, IL-6 and TNF-α were analyzed with 15-week-old sex-matched livers. ns means 
not significant. n=4-5 per group; n=2 per female group; n=2-3 each male group. 
4.3.3 Chronic inhibition of the IKK complex by SR12343 delays lipodystrophy and 
improves metabolic abnormalities in Ercc1-/Δ mice   
Lipodystrophy refers to the absent and altered distribution of adipose tissue, which may occur 
with metabolic abnormalities. Multiple progeria mouse models, such as Zmpste24-/-, Ercc1-/-, and 
aP2-Ercc1F/-, have been shown to exhibit reduced fat depots similar to naturally aged WT mice 
(177, 236). We employed nuclear magnetic resonance (NMR) to determine the body 
composition, including fat, lean tissue and fluid, in Ercc1-/Δ mice (237). We found a gradual 
decline of fat depot with aging starting from 8 weeks, which paralleled the onset of aging 
symptoms. In particular, severe loss of fat was observed around 14 weeks of age, at which point 
Ercc1-/Δ mice contained close to 0% body fat (Fig. 23A). However, a delayed loss of fat was 
found in SR12343 treated mice, suggesting that suppression of NF-κΒ could attenuate the 
progression of lipodystrophy. An association of impaired glucose tolerance with reduced body-
fat mass has been established and has been linked to reduced production of leptin (238-240). To 
determine if metabolic abnormality could be improved by suppressing IKK/NF-κB, an oral 
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glucose tolerance test (OGTT) was conducted on mice fasted overnight. Accelerated clearance 
and lower peak serum glucose were found in mice treated with SR12343 (Fig. 23B). To 
determine whether the levels of cellular senescence were altered in adipose tissue, SA-βgal 
staining was performed with parametrial fat, which showed reduced staining in treated mice, 
indicating less senescence in fat (Fig. 23C). Taken together, inhibition of IKK/NF-κB by 
SR12343 improved lipodystrophy and associated glucose intolerance, likely due to the lowered 










Figure 23: SR12343 attenuates lipodystrophy and glucose intolerance in Ercc1-/Δ mice. (A) 
NMR was performed weekly on SR12343 treated or untreated mice from 6 to 14 weeks of age. 
Percentage of fat in males is shown and was normalized to the level at 6 weeks of age. n=3-4 
each group. (B) Ercc1-/Δ mice fasted overnight were dosed with a bolus of glucose (2g/kg) by 
oral gavage and blood glucose was measured at 0, 5, 15, 30 and 60 min. The fasting blood 
glucose was measured prior to the dosing of glucose. n=4-5 each group. (C) Fresh parametrial fat 
collected from 15-week-old Ercc1-/Δ mice was stained for SA-βgal. Representative images taken 
5 hr into the staining are shown. Two-tailed Student’s t-test was used to determine the p value. 
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4.4 DISCUSSION 
In this study, we demonstrated that pharmacologic inhibition of IKK/NF-κB by a novel NBD 
mimetics (SR12343) substantially prolonged healthspan by reducing senescence in multiple 
tissues. Intriguingly, a lipodystrophy-associated metabolic abnormality was also attenuated by 
IKK/NF-κB inhibition. Our study further supports a causal role of IKK/NF-κB in aging, 
consistent with the effects of knocking down Rel/p65 in Sirt6-/-, Ercc1-/Δ and Zmpste24-/- 
progeroid mice (136-138, 241). Although anti-inflammatory drugs, such as curcumin and 
metformin, have been shown to have therapeutic effects in diabetes and multiple aging-related 
diseases, these drugs have a broad range of targets (242). Thus, a selective IKK inhibitor 
(SR12343) was used in this study to dissect the role of IKK/NF-κB in regulating aging. Notably, 
we demonstrated that a single drug specifically targeting IKK could simultaneously improve 
healthspan and multiple aging-related diseases. 
We found that the chronic treatment of progeroid mice with a specific IKK inhibitor 
(SR12343) could delay the onset, reduce the severity and slow the progression of aging 
symptoms, in line with previous evidence that NF-κB activation drives aging pathology (137). In 
addition, aging-related neurodegeneration has been an emerging problem since human lifespan 
has been remarkably prolonged. Multiple neurological symptoms, such as dystonia, gait disorder, 
hindlimb paralysis and ataxia, were improved by SR12343 in Ercc1-/Δ mice. However, it remains 
unknown if this is due to systemic or local (in CNS) effects of NF-κB inhibition.  
Chronic SR12343 treatment reduced cellular senescence in liver and adipose tissue, as 
demonstrated by the reduction in SA-βgal staining. This suggests the prolonged and improved 
healthspan is likely mediated by the reduction of cellular senescence and the attenuation of  cell-
nonautonomous pathway. Notably, the reduction of cellular senescence is not mediated by a 
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senolytic effect as reported by Kirkland et al (90). Thus SR12343 represents a different category 
of drugs which reverse or prevent the development of cellular senescence in vitro and in vivo. 
Notably, Ercc1-/Δ mice treated with NBD peptide appear to exhibit a healthier phenotype 
compared to p65+/-:Ercc1-/Δ mice, suggesting the involvement of NF-κB-independent pathways 
in DNA damage-induced premature aging (137). There is evidence suggesting that IKK 
suppresses the translational activity of FOXO3a, which is associated with longevity by 
protecting against oxidative stress (243). Moreover, IKKβ has been shown to crosstalk with the 
mammalian target of rapamycin (mTOR) pathway, regulating the phosphorylation and activation 
of ribosomal protein S6 and eukaryotic initiation factor 4E binding protein 1 (4EBP1) (244). 
Thus, further exploration is needed to determine whether SR12343 simultaneously regulates NF-
κB-independent pathways.  
Using NMR, we were able to monitor aging-associated alteration of body composition in 
real-time. Here, we discovered a gradual but significant decline of fat depots in Ercc1-/Δ mice, 
while body weight and percentage of lean mass remained unchanged (data not shown). 
Intriguingly, the loss of fat coincides with the onset of most aging symptoms, implicating that its 
occurrence is indeed aging-related. Moreover, pharmacologic inhibition of IKK by SR12343 was 
able to slow down the loss of fat depots in male group, supporting the hypothesis that chronic 
inflammation may impair adipogenesis and alter fat distribution, This is in agreement with 
previous studies reporting that lipodystrophy observed in aP2-Ercc1F/- and Ercc1-/- mice may be 
a consequence of a chronic pro-inflammatory response induced by persistent DNA damage 
(177).  
Among interventions that prolong healthspan and/or lifespan are caloric restriction, 
growth hormone receptor deletion (GHRKO), insulin receptor substrate-1 and S6-kinase-1 
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knockout and rapamycin treatment, all of which display reduced fat mass, while obesity appears 
to accelerate aging leading to a reduced lifespan (245-247). Senescent adipose tissue has been 
previously associated with metabolic abnormalities, such as obesity and diabetes, where 
adipocytes in fact undergo senescence and express various senescent markers, including SA-
βgal, γH2AX, p16, p21 and SASP components (247-249). However, most studies were 
performed to study the relationship between cellular senescence and positive energy balance. 
Here we wanted to understand the role of cellular senescence in negative energy balance, which 
is commonly associated with aging and premature aging induced by HIV treatment of 
combination antiretroviral therapy (cART) (250). We demonstrated cellular senescence in the 
adipose tissue of Ercc1-/Δ mice, which is associated with the aging-related lipodystrophy, the 
opposite of obesity. Thus, it is plausible that there is a common mechanism connecting both 
positive and negative energy accumulation to aging in adipose tissue. Interestingly, our study 
indicates that SR12343, which suppresses IKK/NF-κB activity, could improve the broader aging-
related metabolic profile in Ercc1-/Δ mice.  
Impaired glucose tolerance has been reported in aP2-Ercc1F/- mice, where insulin 
production was greatly increased, suggesting the presence of Type 2 diabetes (177). Our 
previous study also reported dyslipidemia in Ercc1-/Δ mice by showing significantly elevated 
serum cholesterol but not triglyceride, which correlates with hepatic steatosis demonstrated by 
H&E staining (251). Specifically, a detrimental role of low-grade chronic inflammation in 
obesity and insulin resistance has been substantially documented (252, 253). Mice expressing 
constitutively active IKKβ in liver exhibited chronic inflammation and a Type 2 diabetes 
phenotype (254). In this study, we found impaired glucose metabolism in Ercc1-/Δ mice in which 
glucose clearance was significantly delayed. SR12343 was shown to improve glucose clearance, 
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supporting the hypothesis that chronic inflammation in liver, adipose tissue and likely pancreas, 
contributes to glucose intolerance.  
Taken together, we found that a novel NBD mimetic (SR12343) showed therapeutic 
effects in extending healthspan and attenuating metabolic abnormality in premature aging. This 
was demonstrated to be mediated by reduced cellular senescence in tissues and dampened 
systemic inflammation. Our results suggest that IKK/NF-κB is a key target for the management 
of healthy aging and SR12343 could be a promising approach to improve aging and aging-
related diseases.  
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5.0  DISCUSSION AND FUTURE DIRECTIONS 
5.1 GENERAL DISCUSSION  
NF-κB is a family of pleiotropic transcription factors involved in multiple biological events. This 
pathway is activated by distinct cellular stress, such as inflammation, oxidative stress and 
genotoxic stress (3). Mounting evidence highlights that NF-κB activation is strongly associated 
with aging in both humans and rodents (136). We and others previously reported that reduction 
of p65/RelA genetically or pharmacologically could extend healthspan as well as improve aging-
associated pathology in Zmpste24-/- and Ercc1-/Δ progeria mouse models (137, 138). An essential 
role of elevated DNA damage response (DDR) has also been highlighted in numerous aging 
studies (62, 235). Moreover, Miyamoto and colleagues established a molecular linkage between 
ATM and NF-κB in response to DNA damage (4). Thus we hypothesize that accumulative DNA 
damage and subsequent activation of DDR are the driving forces of aging and result in NF-κB 
activation in Ercc1-/Δ mice, a DNA repair-deficient murine model. 
In the first part of this thesis, I confirmed an elevated NF-κB activity in Ercc1-/Δ and WT 
mice, which is consistent with our previous finding using NF-κBeGFP reporter mice (137). An 
increased DDR signaling was also found in aged tissues, which occurs concomitantly with NF-
κB activation. In vitro assays suggest that the elevated NF-κB activity is at least in part induced 
by DNA damage, via nuclear-localized ATM and NEMO. Intriguingly, I observed reduced 
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cellular senescence in passage 5 senescent Ercc1-/- MEFs either treated with ATM inhibitor or 
with one Atm allele deleted. Moreover, reduced nuclear-localized NEMO was found after the 
treatment of ATM inhibitor. My results suggest a causative role of DDR activation in cellular 
senescence, which also mediates an ATM- and NEMO-dependent NF-κB activation.  
            To better elucidate the role of DDR signaling in premature aging, Atm+/-;Ercc1-/Δ mice 
were generated. Atm haploinsufficiency resulted in downregulated DDR signaling, as shown by 
reduced expression of ATM, γH2AX and p21. This observation correlates well with dramatically 
reduced phospho-p65 and total IκBα, indicating that elevated NF-κB levels in Ercc1-/Δ mice are 
at least in part attributable to the activation of DDR signaling. A similar response was also 
detected in p65+/-;Ercc1-/Δ mice, however γH2AX was unchanged, confirming our hypothesis 
that DDR proteins lie upstream of NF-κΒ dimers.  
Finally, I demonstrated that ATM heterozygosity was able to extend healthspan in Ercc1-
/Δ mice showing ameliorated neurodegeneration. As Baker et al. demonstrated that removal of 
p16 positive cells prolonged healthspan in BubR1H/H mice, I propose that the alleviated aging 
phenotype may be mediated by reduced cellular senescence (122). Indeed, a reduction of cellular 
senescence was demonstrated in multiple tissues in Atm+/-;Ercc1-/Δ mice, as determined by 
reduced p21 and IL-6 expression. These results strongly support the hypothesis that aberrant 
DDR activation plays a causative role in both cellular senescence and aging, partly by inducing 
NF-κB activation. This hypothesis was further supported by evidence showing better kidney 
function and disc health, along with better function of muscle-derived stem/progenitor cells. 
Although elevated DDR signaling has been associated with aging by numerous studies, 
the data presented in this thesis pinpointed DDR activation as a causative factor of aging. 
However, conflicting roles of ATM reduction in aging have been reported. It is important to note 
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that ataxia-telangiectasia (A-T) patients exhibit segmental premature aging symptoms, in 
particular cerebellar degeneration, which is contradictory to the finding in this study (53). 
Primary Atm-/- MEFs have been shown to exhibit accelerated cellular senescence compared to 
WT MEFs (255). These accelerated senescence and aging phenotypes have been linked to the 
cytoplasmic functions of ATM kinase, particularly in response to oxidative stress (256-260). 
Thereby, it would be critical to investigate the state of redox balance, such as levels of ROS and 
oxidative DNA damage, in vitro and in vivo where ATM is reduced genetically or 
pharmacologically. Moreover, ATM has been demonstrated to negatively regulate mTORC1 
activity via LKB1 and AMPK (79). As caloric restriction and rapamycin treatment, both of 
which are negatively modulators of mTOR, have been reported to significantly elongate 
longevity, future studies could be performed to investigate mTOR activity in ATM 
haploinsufficiency. Furthermore, ATM protein has been implicated in mitophagy, i.e. the 
destruction of abnormal mitochondria, the dysregulation of which has been related to 
neurodegeneration and aging (261). Thus, further exploration of the cytoplasmic functions of 
ATM kinase would be important before translating this study for clinical intervention. 
The second part of this thesis focused on the development of small molecule inhibitors 
mimicking NBD peptide to selectively inhibit IKK/NF-κB activation. A bioinformatic approach 
identified two small molecules (SR12343 & SR12460) that were able to inhibit canonical NF-κB 
activation, without inducing significant cellular toxicity. As NBD peptide has been reported to 
disrupt preformed IKK complexes, in particular the association between NEMO and IKKα/β, I 
propose that these NBD mimetics inhibit NF-κB activation through similar mechanisms (41, 43). 
I demonstrated that SR12343 and SR12460 disrupted the binding of IKKβ and NEMO to a 
similar extent to NBD peptide, especially SR12343, which exhibited even greater disruption. 
 114 
More importantly, in a mouse model of LPS-induced acute lung injury, SR12343 and SR12460 
demonstrated inhibitory effects on NF-κB target genes. A predominant role of IKK/NF-κB 
activation has also been established in promoting macrophage activation and muscle 
degeneration in mdx mice, and NBD peptide has demonstrated profound therapeutic effects in 
murine and canine models of Duchenne muscular dystrophy (48, 52). I demonstrated reduced 
muscular necrosis, attenuated pro-inflammatory infiltration and increased muscle regeneration in 
mdx mice treated with SR12343 and SR12460, which were associated with increased grip 
strength. Thus, my results support previous finding that IKK/NF-κB dysregulation is a major 
contributor to the pathology in Duchenne muscle dystrophy. Moreover, SR12343 and SR12460 
demonstrated similar efficacy to NBD peptide in vivo. 
In the third part of my thesis, SR12343 was tested in Ercc1-/Δ mice to define the interplay 
between NF-κB and aging-associated pathology. We previous reported that p65/RelA 
haploinsufficiency or treatment with NBD peptide extended healthspan in Ercc1-/Δ mice, likely 
via the reduction of mitochondrial-derived oxidative stress (137). The results presented here 
suggest that SR12343 significantly improved and extended the healthspan of Ercc1-/Δ mice, 
showing equivalent, if not greater efficacy as NBD peptide. Both in vitro and in vivo data suggest 
that the rescuing effects may be mediated by reducing cellular senescence, which implies that 
NF-κB may function to promote the maintenance of senescence, and/or initiation cell-cycle 
arrest in neighboring cells. Current studies support the model that NF-κB may propagate a 
secondary senescence via transcriptional upregulation of its targets genes, such as IL-6, TNF-α 
and IL-1α in vitro (165). Finally, my data suggest that NF-κB inhibition may reshape the 
metabolic profile in progeroid mice by preventing the loss of fat depot and attenuating glucose 
intolerance. This observation is consistent with previous reports that metabolic abnormality is 
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partly attributed to systemic chronic low-grade inflammation (175). I speculate that cellular 
senescence in adipocytes and β cells may contribute to the phenotype by functioning improperly, 
showing impaired secretion of leptin and insulin (238-240). My results demonstrated that NF-κB 
inhibition reduced cellular senescence in adipose tissue, providing indirect evidence supporting 
this hypothesis. Although no overt signs of side effects have been observed in treated mice, for 
future studies it would be important to determine liver and kidney toxicity carefully. To elucidate 
the role of NF-κB in aging-related metabolic abnormality, further studies could be done to 
characterize the senescence and functional profile of β cells, adipocytes and preadipocytes using 
SR12343. 
Overall, this thesis demonstrated a causative role of aberrant DDR activation in 
premature aging and indicated a subsequent activation of ATM/NEMO-dependent NF-κB 
pathway. I developed NBD mimetics, which are small molecule inhibitors of IKK/NF-κB 
functioning similar to NBD peptide, and demonstrated that they have similar inhibitory and 
therapeutic efficacy to NBD peptide in vivo. Finally, using the NBD mimetic, I showed a 
deleterious role of NF-κB in regulating tissue senescence and systemic metabolism. To further 
confirm that ATM and NEMO mediate the NF-κB activation, NEMO-DK (K277A and K309A) 
mice where genotoxin-induced NF-κB activation is specifically blocked, will be utilized to 
determine the role of cell-autonomous pathway in cellular senescence, and aging (262). 
Furthermore, as SASP has been long speculated to mediate secondary senescence in vivo, mouse 
models with deleted TNFR or MyD88 will be studied to determine the role of SASP factors, 
such as TNF-α, IL-1α, IL-1β and IL-6, in cellular senescence and aging. 
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5.2 DNA DAMAGE-INDUCED AGING MODEL 
 
Figure 24: Aging model. Telomere shortening, oxidative stress and genotoxic stress induce 
cellular senescence by triggering a persistent DNA damage response. Upon DNA damage, 
ATM/ATR is activated and rapidly recruits, phosphorylates and activates an important DDR 
protein, γH2AX. In parallel, activated ATM leads to the activation of CHK2, which in turn 
stabilizes p53, leading to upregulated transcription of p21, a cell-cycle regulator. p21 then 
imposes an irreversible G1 cell-cycle arrest, leading to the establishment of cellular senescence. 
Our data suggest that ATM/ATR does not regulate the p16/Rb pathway directly, as ATM 
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haploinsufficiency showed no significant reduction in p16 expression. In addition, our data 
indirectly support an activation of ATM/NEMO-mediated NF-κΒ pathway, which leads to a 
SASP phenotype. However, it is still unknown if GATA4 is also involved as a mediator 
connecting ATM and NF-κB signaling in Ercc1-/Δ mice. As SASP factors, such as TNF-α and 
IL-1, are not only target genes of NF-κΒ, but also activators of NF-κΒ. SASP is speculated to 
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